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Abstract 
Parkinson’s disease (PD) is a common neurodegenerative disorder. Recent evidence points towards 
increased synchronous neuronal oscillations of the cortico-thalamic-basal ganglia circuits in the 
beta band (12–30 Hz) as the main pathophysiological abnormality associated with PD. Deep brain 
stimulation (DBS) of the subthalamic nucleus (STN) is an effective treatment for improving PD 
motor symptoms. However, the current DBS systems have several limitations, mainly related to the 
fixed and continuous application of stimulation. Especially in the long-term, DBS can only partially 
control clinical fluctuations and can exacerbate undesirable adverse effects often reversible with a 
change of stimulation parameters. A new strategy called adaptive DBS (aDBS) allows for 
continuous adaptation of STN stimulation to the patient’s clinical state by directly harnessing the 
recordings of the STN pathological oscillatory activity or local field potentials (LFPs).  
At present, however, the lack of understanding of DBS and PD pathophysiological mechanisms, 
represents a challenge to the realization of aDBS devices. Despite the evidence that LFPs 
(especially beta oscillations) correlate with a wide spectrum of PD motor and non-motor symptoms, 
whether or not the statistical correlation is enough for controlling DBS remains unclear. 
With this project, we aimed to accelerate the clinical translational process by suggesting a pathway 
to the clinical practice. To do so, we developed an external portable LFPs-based aDBS device for 
clinical investigations in acute experimental sessions, which we validated in vitro and in vivo 
(Chapter 2). We then conducted a proof of concept study investigating the functioning of the device 
and comparing aDBS and conventional DBS (cDBS) and how they interacted with the concurrent 
pharmacological treatment (Chapter 3). Then, in a second proof of concept study, we monitored the 
clinical and neurophysiological fluctuations over a period of eight hours with and without aDBS. 
We thus investigated the preservation of LFPs-clinical state correlation and the aDBS management 
of motor fluctuations during daily activities (Chapter 4). Because in the clinical practice the DBS 
therapy is provided by means of implantable pulse generators (IPGs), we evaluated whether the 
proposed aDBS approach, based on real-time LFPs processing, fits the power constraints of 
implantable devices (Chapter 5). Finally, we contextualized our results and proposed an overview 
of the possible pathways toward the clinical practice (Chapter 6).   
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1 Introduction 
1.1 Parkinson’s disease 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder caused by the death of the 
cells in the substantia nigra (SN) (Lang & Lozano, 1998). After Alzheimer’s disease, PD is the 
second most common neurodegenerative disorder for diffusion. Globally there are almost 5 million 
people effected by PD (Muangpaisan et al., 2011), and a projection study reported that between 
2007 and 2030 the number of cases will double (Dorsey et al., 2007). The etiology of PD remains 
unclear. Both environmental and genetic factors contribute to the onset of the disease.  
Parkinson’s disease is mainly characterized by three cardinal symptoms: bradykinesia, rigidity and 
tremors (Lang & Lozano, 1998). However, it is a complex disease that presents a wide spectrum of 
motor and non-motor symptoms. Bradykinesia refers to a slowing of movement and a prolonged 
time between a movement’s initiation and completion. The term is sometimes used as a synonym of 
hypokinesia, and its more severe form akinesia, although bradykinesia emphasizes delayed 
execution time and akinesia delayed reaction time (Berardelli et al., 2011). Rigidity refers to an 
alteration of the tone of muscles even when the patient is in a relaxed condition. Tremor is a 
rhythmic movement, with a frequency ranging between 4 and 6 Hz, generally involves hands, and 
occurs when the patient is at rest. When motor symptoms appear, the SN has already lost 60–80% 
of dopaminergic neurons. 
At present, the neurodegenerative process of PD patients cannot be reversed or stopped, and 
existing treatments can only manage the disease and relieve the symptoms. The most effective 
treatment is the pharmacological treatment based on levodopa administration 
(L‑ dihydrophenylalanine). Levodopa can ameliorate motor symptoms, but has a few side effects. 
This treatment is valid in the short term, because, in the long term, motor fluctuations and 
dyskinesias occur in association with levodopa therapy (Del Sorbo & Albanese, 2008). 
Antiparkinsonian medication guarantees good motor control for an average interval of four to six 
years, after that the benefit induced by dopaminergic treatment starts wearing off after four to five 
hours. This window of time becomes progressively shorter with the progression of the disease, and 
the state of the patient begins to fluctuates (motor fluctuations) between the “on” time (when the 
medication attenuates symptoms) and “off” time (when the mediation has no effects). After months 
or years, the patients start to experience peak-dose levodopa dyskinesias, which consists of 
involuntary movements occurring during peak levels of dopamine concentration. The management 
of motor fluctuations at this stage of the disease requires a trade-off between the levodopa dose 
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needed to effectively improve motor symptoms and the dose that will avoid peak dose dyskinesias. 
The ideal therapy should therefore minimize “off” time and avoid peak dose dyskinesias during 
“on” time; however, the therapeutic window narrows over time. Finally, when the motor 
fluctuations cannot be adequately controlled by medication, surgery for deep brain stimulation 
(DBS) is considered. 
Deep brain stimulation is an invasive treatment based on high-frequency electrical stimulation of 
deep brain areas. It is considered for the clinical treatment of PD, dystonia and essential tremor 
(ET), and experimental studies are ongoing for its use in treating a wide range of other neurological 
disorders. The DBS electrodes are surgically implanted, and they deliver electrical stimulation 
generated by an implantable pulse generator (IPG). A more detailed description of the DBS is 
presented in the following sections.  
1.2 Functional anatomy and physiology of the basal ganglia 
The basal ganglia (BG) are a part of the motor system consisting of a group of subcortical nuclei 
including the subthalamic nucleus (STN), striatum (dorsal striatum: caudate nucleus, putamen; 
ventral striatum: nucleus accumbens), globus pallidus and subtantia nigra pars reticulata (SNr) 
(Albin et al., 1989). The globus pallidus is divided into the internal (GPi) and the external (GPe), 
and the SN is divided into the substantia nigra pars compacta (SNc), dopaminergic neurons, and 
SNr, along with neurons related to gamma-aminobutyric acid (GABA) receptors (i.e. GABAergic 
neurons) (Fig. 1.1).  
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Figure 1.1 The anatomy of basal ganglia (image source: JA Obeso et al.2014) 
As described by Fig. 1.2, the striatum represents the input point of the BG, while the outputs are the 
STN, GPi, GPe. The cortical excitatory signals first reach the striatum and then are propagated over 
the direct and the indirect pathway, respectively, toward the GPi and STN and GPe. More recent 
models also highlight the relevance of the hyperdirect pathway between the cortex and the STN. 
This classical model provides a heuristic explanation of cardinal PD symptoms as a result of a 
modified equilibrium between the direct and indirect pathways, and today, despite its 
oversimplification, this explanation still maintains its core validity (DeLong, 1990; Herrington et 
al., 2016). More recent models highlight also the relevance of the hyperdirect pathway between the 
cortex and the STN, and other more complex network mechanisms (not discussed here, for 
simplicity). The loss of dopamine neurons in the SNc results in a disruption of the striatal 
physiology. It is thought that in the normal state (Fig. 1.2a), dopamine inhibits the indirect pathway 
and excites the direct pathway. In the parkinsonian state (Fig. 1.2b), the striatal neurons of the direct 
pathway that express dopamine D1 receptors become less active as a consequence of dopamine 
depletion, whereas those that bear dopamine D2 receptor-bearing in the indirect pathway are more 
active. When this happens, the GPe is inhibited, and the STN is excited. The STN has an excitatory 
projection to the GPi, which results in the inhibition of thalamocortical and brainstem motor centers 
(Obeso et al., 2014). 
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Figure 1.2 Functional basal ganglia model (image source: Herrington et al.2016) 
 
Despite this anatomo-functional model, the mechanisms of the pathophysiology of BG leading to a 
parkinsonian state remains unclear. We here discuss the main theories, classified as proposed by 
Chiken and Nambu (2016).  
Firing rate model. The firing model is based on the above-mentioned classical model (Albin et al., 
1989; DeLong, 1990). The dopamine depletion results in excessive GPi and SNr firing (“firing 
rate”), which inhibits the thalamocortical output. Conversely, a reduced GPi firing rate would cause 
a lack of inhibition of the thalamo, resulting in involuntary or hyperkinetic movements. Such a 
model can, therefore, explain both hypokinetic and hyperkinetic disorders and has also found 
confirmation in PD animal models (Bergman et al., 1990).  
Firing pattern model. The excessive coupling between GPe and STN, caused by the loss of 
dopamine cells, can enhance oscillatory activity in the BG loop. This model is based on the 
assumption that oscillatory activity detected in the nuclei of the BG, STN, GPe, and GPi originates 
from abnormally increased synchronizations of single neurons that, in turn, lose the ability to 
adequately process motor information.  
Dynamic activity model. This model is based on the hypothesis that in normal state the desired 
motor program is realized through time-locked changes at the level of the GPi, resulting in GPi 
inhibition or excitation depending on the specific motor task. If the potential to modulate the GPi 
dynamically decreases then the BG results in a reduced or increased thalamocortical activity 
depending on the balancing between the indirect and direct pathways (Nambu et al., 2015).    
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1.3 Deep brain stimulation 
1.3.1 Deep brain stimulation mechanisms 
Although deep brain stimulation (DBS) has proven to be an effective treatment for hypokinetic and 
hyperkinetic movement disorders, the mechanisms by which it achieves results are still under 
debate. In PD, the prevalent sites of implant are the STN and the GPi, which provide the best motor 
outcomes. Here, we present the three cardinal hypotheses concerning DBS mechanisms, but a 
deeper discussion, including recent findings, is offered in the final chapter.    
Inhibition hypothesis. Because DBS and lesion therapy have been shown to induce similar 
improvements in the motor symptoms (Benabid et al., 1994), it has been suggested that the 
mechanism of action of DBS was the inhibition of the neurons around the electrode. A reduction of 
the output of the site of implant was found in human recordings (Dostrovsky et al., 2000; Welter et 
al., 2004) and in animal models (Benazzouz et al., 2000). Mechanisms that might explain the 
inhibitory effect of DBS include depolarization block, inactivation of voltage-gated currents, and 
activation of inhibitory afferents (Chicken & Nambu, 2016). 
Excitation hypothesis. Successive studies have shown that DBS also has an excitatory effect, 
resulting in increased activity of the downstream nuclei. In a parkinsonian monkey, the activity of 
the GPi was increased by means of STN stimulation (Hashimoto et al., 2003). This effect, despite 
sounding paradoxical, finds an explanation in that DBS, while inhibiting local cells body, excites 
efferent and afferent fibers. Modeling studies confirmed that axons are sensitive to DBS (McIntyre 
et al., 2004), and spikes are locked in time with stimulus.   
Informational lesion and prokinetic oscillation enhancement. These theories are grounded in the 
hypothesis that abnormal oscillatory activity diffused over the entire BG network can be disrupted 
(informational lesion) or substituted with a more physiological effect (prokinetic oscillation 
enhancement) by high-frequency stimulation, thus preventing the spread of the pathological 
rhythmic and information contents.  
1.4 Adaptive deep brain stimulation 
1.4.1 The concept and rationale of adaptive deep brain stimulation 
Despite the evidenced clinical outcomes of DBS, this treatment still suffers from adverse motor 
symptoms and suboptimal clinical fluctuations control. For instance, the adjustment of stimulation 
parameters can help to avoid motor symptoms induced by STN-DBS (Bronstein et al., 2011; Yu 
and Neimat, 2008; Frankemolle et al., 2010) stimulation-induced hemiballism (Limousin et al., 
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1996; Limousin et al., 1998), and motor side effects such as dyskinesias (Hamani et al., 2005), 
speech and gait (Bronstein et al., 2011). Moreover, it was noted in a long-term follow-up study that 
the higher the number of follow-up visits for DBS parameters adjustment is, the more positive the 
DBS clinical outcomes are (Moro et al., 2006). For all these reasons, DBS needs further 
improvement. The recent research and technological innovations in the field of neurophysiology, 
neuroimaging, and neural engineering are providing new opportunities to explore the PD 
pathophysiology and DBS mechanisms, and they are moving toward a process of DBS therapy 
personalization. In the effort to cluster such innovations, we identify two main directions (Fig. 3): 
DBS space resolution improvement, which includes current steering (Barbe et al., 2014; Pollo et al., 
2014) and dual stimulation (Sims-Williams al., 2013); and DBS time resolution improvement, that 
is, adaptive deep brain stimulation (aDBS) (Priori et al., 2013) and coordinated reset (CR) 
(Adamchic et al., 2014). Data collection, mediated by an online database, constitutes a third 
direction, which provides useful information through data mining (Rossi et al., 2014). However, 
technological innovations may not find clinical application, and further steps, especially in the basic 
research, are needed to prove their effectiveness and feasibility. In this scenario, the idea of an 
“intelligent” DBS system, which can adapt stimulation parameters over time in relation to symptom 
fluctuations and adverse effects, has garnered much interest (Burgess et al., 2010; Rosin et al., 
2011; Santaniello et al., 2011; Winestone et al., 2012) and has been generally referred to as “aDBS” 
or “closed-loop DBS” (Fig.).  
 
Figure 1.3 Technological innovations 
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An aDBS system should update stimulation parameters, based on a control variable or a set of 
control variables that reflect the patient’s clinical state. 
 
 
Figure 1.4 Adaptive DBS model (image source: Priori et al.2012) 
At present, the concept of aDBS is widely pursued in the literature, but concrete evidence about its 
applicability are still lacking and different approaches and strategies have been proposed to 
accelerate the translational process. To this end, several critical issues need to be overcome, firstly 
the choice of the control variable and the feedback algorithm, the technical constrains of 
implantable devices (size and power consumption) and the practical consequences, such as changes 
in the surgical procedures and the need for additional devices.    
Ideally, the optimal aDBS system should improve the clinic outcomes of conventional DBS without 
implying changes in the surgical procedures or adding more devices, unless they alleviate or 
overcome the discomfort of the patient. Moreover, because the PD clinical signs vary with the 
phenotypical features of the disease, the possibility that more than one optimal aDBS strategy exists 
cannot be ignored, well as the use of a more than one control variable or feedback algorithm.  
In the following sections, we review the current approaches classified on the basis of the control 
variable, its consequences from the perspective of technological design and surgical procedure, and 
its goodness as a biomarker for a specific PD clinical sign. 
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1.4.2 Control variables 
 
Figure 1.5 Proposed control variables for aDBS 
Surface EMG and accelerometers. Surface electromyography (sEMG) and accelerometers have 
been proposed to detect, predict, and control tremors in PD (Basu et al., 2013; Shoukla et al., 2012) 
and in ET patients (Basu et al., 2011; Shukla et al., 2013; Yamamoto et al., 2012). Algorithms 
based sEMG and accelerometer signals recorded at the symptomatic limb have performed very well 
in in tremor prediction, achieving an accuracy of 80% and a sensitivity of 100% (Basu et al., 2013). 
Surface EMG and accelerometer signals can be recorded by means of wearable devices, which 
implies wireless communication with the IPG to trigger or modulate stimulation. Current DBS 
systems already have telemetry links and, conveniently, the feedback algorithm can be executed on 
the wearable device, thus exploiting higher processing possibilities. This capability would not 
require changes in the design of the device and, as consequence, in the surgery procedures. 
However, wireless links in implantable devices are based on inductive coupling or 2.4 GHz RF 
protocols; in the first case an additional device aligned with the coil of the IPG would be needed, 
and in the second, current drawn from the battery would drastically increase. Moreover wearing 
external devices could be uncomfortable and unmanageable for the patient. While accelerometer 
signals are easily detectable, sEMG is effected by several sources noise (Clancy et al., 2002), and 
long-term consistency is influenced by factors such as electrode positioning, motion, and contact 
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impedances. Lastly, using sEMG and accelerometers does not allow one to track other cardinal 
symptoms, such as rigidity. 
Cortical neuro signals. Single- and multi-unit activity and electrocorticography (ECoG) have been 
widely investigated for neuroprostheses (Tsu et al., 2015) and epilepsy closed-loop devices (Vonck 
et al., 2015). Single- and multi-unit activity signals ensure high temporal and spatial resolution 
(Stavinsky et al., 2015) and are mainly recorded by means of micro-electrode arrays (MEAs), thus 
exhibiting low signal stability over time (Shenoy et al., 2014). Electrocorticography-based 
implantable devices for seizure detection are, instead, already commercially available for chronic 
applications (Sun et al., 2014). Multi-unit activity and ECoG have been studied in PD patients and 
PD animal models (monkey) to better understand the processing mechanisms of cortical-basal 
ganglia circuits and to develop closed-loop strategies (Rosin et al., .2011; de Hemptinee et al., 
2015).  
Reportedly, providing short train of DBS pulses (seven pulses at 130 Hz), in a 1-methil-4-phenyl-
1,2,3,6-tetrahyhydropyridine (MPTP) primate model of PD implanted in the GPi, 80 ms after an 
action potential is detected from the motor cortex (M1 area) can concurrently reduce akinesia and 
pallidal oscillations more than conventional DBS (Rosin et al., 2011). 
Recently, Hemptinne et al. (2015) showed that in ECoG signals recorded form M1 motor cortex of 
PD patients, the phase-amplitude coupling (PAC) between beta and gamma oscillations is 
significantly reduced for motor tasks, and rigidity improvements. 
From the physiological perspective, it is, therefore, reasonable to use cortical signals as a control 
variable, considering also that the distance from the stimulating area would prevent or decrease the 
stimulation artifact. However, sensing electrodes should be hypothetically distributed over a wide 
cortical area to cover function connections. Finally, employing new sensors implies introducing 
changes in the surgical procedures.  
Neurochemical signals. Stimulation can induce dopamine responses that can be quantified and 
potentially used as a control variable (Chang et al., 2013). The dopamine release can be measured 
through carbon fiber microelectrodes (CFMs) for in vivo fast-scan cyclic voltammetry. These 
electrodes have been implanted in the striatum of four anaesthetized rats to characterize the 
relationship between dopamine levels and stimulation parameters (Crahn et al., 2014). Interestingly, 
DBS determinates increased level of dopamine for a duration comparable to tremor-free periods 
(Graupe et al., 2014). Despite that neurochemical signal measurements have important implications 
in unveiling DBS mechanisms, their applicability in experimental and clinical in vivo protocols in 
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humans still faces technical issues (four adjunctive electrodes are necessary, and the lifetime of 
CFM is limited to a few months) (Chang et al., 2013). 
Basal ganglia (BG) local field potentials. The introduction of DBS therapy opened the possibility to 
investigate the neurophysiological mechanisms of BG by recording the neuronal activity of the 
target area from the DBS electrodes. The low-frequency oscillatory components of the electrical 
activity of the neuronal population around the electrode are called local field potentials (LFPs), 
representing the state of synchrony of a neural ensemble. 
Consistently with electroencephalography (EEG) oscillations, BG LFP oscillations, can be clustered 
into frequency bands: very low frequencies (LFs) (2–8 Hz), alpha frequencies (8–12 Hz), low beta 
frequencies (12–20 Hz), high beta frequencies (20–35 Hz), gamma frequencies (60–80 Hz), and very-
high frequencies (250–350 Hz). The temporal and frequency features of these oscillations have been 
shown to change in response to the patient's clinical state, during movement execution, and also with 
cognitive and behavioral stimuli (Foffani et al., 2005a; Kuhn et al., 2009; Marceglia et al., 2011). 
The beta oscillatory activity recorded from the STN of PD patients is, at present, the most studied and 
debated frequency band. Beta oscillations are, in fact, modulated by dopaminergic medication (Priori 
et al., 2004) and electrical stimulation (Eusebio et al., 2011; Giannicola et al., 2010), and they 
correlate with movement preparation and execution (Foffani et al., 2005a), akinesia (Kuhn et al., 
2009), and freezing of gait (Toledo et al., 2005). Parkinson’s disease motor and non-motor symptoms 
have also been correlated to other frequency bands: The LFs are associated with the occurrence of 
dyskinesias (Foffani et al., 2005b; Alonso-French, 2006), the alpha correlates with the gait speed 
(Thevathasan et al.), and the gamma has a prokinetic role (Florin et al., 2013). Because of the 
correlation with the major clinical signs of PD, the LFP has been proposed as control variable (Priori 
et al., 2013; Little et al., 2012).  
From a technological perspective, the implanted DBS electrodes are suitable for long-term 
recordings. Classical models of DBS microelectrodes (i.e. Model 3389, Medtronic, Minneapolis, 
USA) are fabricated with platinum-iridium (Pt-I) cylindrical contacts with a large surface, along with 
low and stable impedances. Therefore, an aDBS device, based on LFPs would not need any additional 
electrodes or external implants, thus leaving the technical procedure unchanged. On the other hand, 
they anyway require the modification of the electronic board of IPGs in order to add analog circuits 
for neuro-signal recordings that are technically feasible (Rouse et al., 2012). 
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the implanted 
DBS electrode. 
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Changes in the surgical 
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procedure. 
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needs to include the 
implant of cortical 
electrodes. 
NO – No 
additional 
implant is needed 
during surgery. 
YES – The additional 
CFMs need to be 
implanted during surgery. 
Patient’s 
management/acceptability 
NO – It may be 
difficult to manage 
the recording sensors, 
and the external 
equipment may be 
uncomfortable. 
YES – All the 
equipment is 
implanted. 
YES – The 
patient receives 
the same system 
as for traditional 
DBS. 
NO – CFMs have a 
lifetime of only a few 
months and have to be 
replaced. 
Correlation with the 
clinical state 
YES or NO – 
Optimal correlation is 
present with the 
tremor, but no 
correlations with 
rigidity and 
bradykinesia. 
YES – ECoG 
phase-amplitude 
coupling and M1 
action potentials 
correlate with main 
PD symptoms and 
can be used to drive 
aDBS. 
YES – Multiple 
LFP oscillations 
are modulated by 
levodopa 
administration, 
DBS, 
movements, and 
non-motor tasks 
even years after 
electrode 
implant. 
YES - The duration of the 
tremor-free period is 
comparable to the 
duration of increased 
levels of stimulation-
induced dopamine release 
after DBS pulse trains. 
Personalization and 
adaptability 
NO – It cannot be 
used if patients do not 
show tremor. 
YES/NO – It may 
encode patient-
specific 
information. 
YES – The 
presence of 
multiple rhythms 
correlating with 
different patient’s 
characteristics 
may account for 
inter-subject 
variability. 
NOT YET TESTED 
Low battery consumption 
YES/NO – The 
processing can be 
done externally, but 
triggers should be 
sent via telemetry 
links. 
YES/NO – The 
IPG needs to 
include the sensing 
circuit and the 
feedback algorithm. 
YES/NO – The 
IPG needs to 
include the 
sensing circuit 
and the feedback 
algorithm. 
NO – The IPG needs to 
include the sensing circuit 
and the feedback 
algorithm. 
Table 1.1 Advantages and drawbacks of proposed control variables for adaptive deep brain 
stimulation (aDBS). 
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2 Design and implementation of an external portable 
device for clinical research of adaptive deep brain 
stimulation  
2.1 Introduction 
We designed, implemented and validated an external portable adaptive deep brain stimulation 
(aDBS) device based on LFP feedback, aiming to investigate neurophysiological and DBS 
mechanisms of action, and aDBS feasibility and efficacy. It was intended for use during 
perioperative experimental sessions in patients having DBS leads externalization. After the surgery 
for DBS electrodes implantation, they can be externalized and used both for recording and 
stimulating. Our goal was to design a device that was portable (to allow the patients to move as 
freely as possible), reprogrammable (to change and allocate new processing and closed-loop 
algorithms) and safe (to avoid unwanted risk for the patients). In this chapter, we discuss the 
requirements and the implementation of the aDBS device, and the validation tests in vitro and in 
vivo. No details are provided at this stage about the closed-loop strategy; here, we focused on the 
validation of its sensing and processing capability. Because an essential feature of the device is to 
change the stimulation parameters in response to a change in the input control variable, we tested its 
feature in vitro with a sample closed-loop algorithm. 
2.2 Design and implementation 
2.2.1 Requirements for sensing local field potentials during deep brain 
stimulation 
The sensing problem. The problem of recording local field potentials (LFPs) during deep brain 
stimulation (DBS) was addressed for the first time by Rossi and colleagues (Rossi et al., 2007), who 
developed a biopotential amplifier able to reject the stimulus artifact from the signal and isolate the 
LFP component. The DBS stimulus artifact consists of harmonics of 130 Hz (Stanslaski et al., 
2012), while the interested frequencies of LFPs, especially beta oscillations, are under 40 Hz. The 
strategy proposed by Rossi et al. (2007) is based on the frequency separation of the stimulation 
artifact by means of a low-pass analog filter following a low gain differential amplification stage. 
The same strategy has been used in other works (Denison et al., 2007; Zbrzeski et al., 2013). An 
alternative solution to the artifact removal problem is the digital subtraction of template matching 
(Hashimoto et al., 2002), but although it can extract LFP content offline it is not suitable for online 
processing. 
 
 
 
19 
 
The low differential gain avoids saturation effects caused by the high magnitude of the stimulation 
artifact compare to the LFPs. The low-pass filter suppresses the stimulation harmonics in order to fit 
the rail-to-rail voltage supply range. Rossi et al. (2007) developed a recording chain having a +/− 15 
V rail-to-rail voltage supply and used off-shields components for the instrument amplifier (INA111) 
and the filter cells (OPA602), the device was sourced by the power line. We here review the 
development requirements proposed by Rossi et al. (2007) to fit the technical constraints of a 
portable device with a lower rail-to-rail voltage supply, lower dimensions, and limited power 
sources.  
Requirements definition. The requirements definition was done on the basis of the previous works 
and LFPs recordings in vivo. In particular, we characterized the LFP signals and the artifact 
magnitude. 
The interested frequency band in LFPs was chosen between 2 and 40 Hz (Rossi et al., 2007), 
including LF, alpha and beta oscillations. The mean power of beta oscillations (+/− 2 Hz the beta 
peak) was reported to be between 1.1 𝜇𝑉𝑟𝑚𝑠 and 7.2 𝜇𝑉𝑟𝑚𝑠 (Yoshida et al., 2012). To confirm 
and expand the requirement, we repeated the measurement in a data sample from previous LFP 
recordings (Marceglia et al., 2006). The data were relative to PD patients recorded from the STN 
after 12 hr of medication withdrawal; for convenience, we hereafter refer to this medical condition 
as the “baseline” clinical state. Each LFP data sample was of a 30 s length, and was divided by the 
total acquisition gain and then filtered between 3 and 30 Hz without phase distortions. The power 
spectral density (PSD) was computed with the Welch method (“pwelch” function, Matlab) with 1 s 
non-overlapping Hanning windows. The windowing operation was done to avoid power leakage 
(Press et al., 1992), but then the result was multiplied for a correcting factor (0.375 for Hanning 
window) to account for the power reduction caused by the windowing. We obtained a peak spectral 
density ranging from 300 𝑛𝑉/√𝐻𝑧 to 1500 nV/√Hz, and a band power ranging between 1.2 and 7.7 
𝜇𝑉𝑟𝑚𝑠, which were consistent with the literature (Yoshida et al., 2012). 
The stimulation artifact was decomposed and characterized as in Rossi et al. (2007). The differential 
part of the artifact was called differential mode artifact voltage (DMAV) and common mode artifact 
voltage (CMAV). We assumed, conservatively, the maximum value of the CMAV to be 10.5 V. 
The DMAV was reported to have a maximum peak-to-peak value of 5 mV (Rossi et al., 2007); 
however, it was obtained in vivo by recording the artifact with a standard amplifier having a high 
corner frequency at 1 KHz, which cuts the high-frequency components of the stimulation artifact, 
thus resulting in a lower peak-to-peak amplitude. To derive a new measure, we used software 
(Matlab) to simulate a stimulus artifact as a train of Dirac’s Delta functions at 130 Hz, then we 
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applied a one-pole low-pass Butterworth filter with a 1 KHz cutoff frequency and 10 KHz, which is 
the intrinsic pole of operational amplifiers. In the latter case, the filtered output was 10 times bigger, 
so we fixed the DMAV at 50 mV instead of 5 mV peak to peak. The DMAV requirement was used 
to regulate the gain and the degree of the low-pass suppression, while the CMAV was used to 
define the common mode rejection ratio (CMRR), which, in general, is always required to be high 
(>100 dB) for bio-potential measures. 
2.2.2 Hardware for sensing local field potentials  
The analog front end for signal recording and stimulation artifact suppression was designed in three 
blocks: differential pre-amplification stage, analog low-pass filtering, final single-ended 
amplification stage. 
 
 
Figure 2.1 a) Schematic block of the analog front-end, b) Schematic representation of the 
differential pre-amplification stage 
The differential amplification stage has been implemented using a commercial instrumentation 
amplifier (Model INA118, Texas Instruments, USA) supplied at +/−5 V. 
To avoid the saturation of the instrumentation amplifier, a passive pre-filtering network was placed 
before the front-end. It provided fully differential high-pass filtering that blocks the DC component 
(Spinelli et al., 2003) and low-pass filtering to smooth the CMAV and the DMAV (−10 dB at 
130 Hz). The differential amplification was set at Gdiff = 46 dB, while the common mode rejection 
was guaranteed by high CCMR of the instrumentation amplifier (INA118). 
In the second stage, we used an eighth-order low-pass Butterworth filter (Model LTC1064-2, Linear 
Technology, USA) with cut-off frequency at 40 Hz to suppress the DMAV, providing −81 dB at 
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130 Hz. The low input noise (10 nV/√Hz) of the selected instrumentation amplifier (INA118) 
guarantees an input signal-to-noise ratio of bigger than 1.  
The final amplification stage includes a single-ended non-inverting amplifier with a fixed gain 
(G = 34 dB). The signal recording was performed with the MSP430FG4618 Mixed-Signal 
Microcontroller (MCU) (Texas Instruments, USA) powered at 3 V, which provided a 12 bit analog-
to-digital converter (ADC) with 1.5 V dynamic range, whose reference was external (+7.25 V). 
2.2.3 Requirements for processing  
As discussed earlier (see Section 1.4.2), the research on local field potentials (LFPs) was based in 
most of cases on the power analysis of the most physiologically relevant bands, low frequencies (4–
7 Hz), alpha (8–11), low beta (12–20 Hz), high beta (20–35 Hz), high gamma (60–80 Hz), and 
300 Hz (270–330 Hz), and their correlation with clinical signs. The occurrence and the duration of 
clinical signs have defined temporal features. Tracking the power changes of a certain frequency 
band is, therefore, a processing requirement. The choice of the temporal resolution for the time-
frequency analysis depends upon the observed phenomena. The de-synchronization of beta 
oscillations induced by levodopa administration have a different time scale (2–5 min; Priori et al., 
2004) than during self-paced movements (0.5/1 s; Foffani et al., 2005), and DBS-induced 
modulations may occur in 3 min (Rosa et al., 2010). The time resolution should be therefore 
programmable, as well as the band selection. Because most studies have selected a 5 Hz band 
around the peak, the desired frequency resolution should be lower than 5 Hz. 
2.2.4 Firmware implementation 
The firmware was implemented on a low-power MCU (MSP430FG4618). The signal was 
digitalized by the ADC peripheral of the MCU at a sampling frequency of 256 Hz. Every second, a 
256-point complex fast Fourier transform (FFT) was computed. The FFT was implemented with the 
Cooley-Tukey algorithm (Cooley & Tukey, 1965). The module of the FFT was calculated between 
5 Hz and 30 Hz, and each frequency bin was normalized for the total power within this band. The 
power of the selected band was calculated and then smoothed iteratively with an exponential 
forgetting factor. Both the band power and the forgetting factor were user selectable.  
Because we based our validation method (see Section 3.1.2) on levodopa-induced modulations of 
beta oscillations, and because of the above-mentioned time course of levodopa-induced 
modulations, we set the forgetting factor to 0.98, leading to a time constant of 50 s.  
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2.3 Validation 
2.3.1 Methods 
2.3.1.1 In vitro experimental set-up 
We configured a workbench experimental set-up to test the sensing and processing features of the 
device. The goal was to emulate the in vivo experimental conditions. To do so we used a DBS 
electrode (Model 3389 Medtronic, Minneapolis, USA) merged in saline solution (0.9% NaCl, 
Bieffe Medical, Italy). The reference for differential recording and for stimulation was simulated by 
two cylindrical Ag-AgCl electrodes (2 mm in diameter, 50 mm in length). The LFPs were 
simplified by a sinusoidal signal created by a waveform generator (Model 33220A, Agilent, USA) 
and input to the saline solution through two additional Ag-AgCl electrodes. To control the 
amplitude of the input signal at the DBS electrode, we used standard amplifier (gain 80 dB, 
passband 1–30 Hz, notch ON) (Model Grass ICP511, Astromed, USA), and we calculated the root 
mean square voltage online with the software Spike 2 (Cambridge Electronic Design, UK) after 
ADC conversion (CED 1401, Cambridge Electronic Design, UK). To control the sensing 
functioning and have a parallel control on the processing outcome, we externalized the signals 
before the ADC of the aDBS prototype, and we recorded them by means of the standard amplifier 
(gain x50, passband 1–100, notch OFF) (Fig. 2.2). The same experimental set-up was already 
validated and used in other works (Rossi et al., 2007; Stanslaski et al., 2012).  
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Figure 2.2 In vitro experimental setup. 
a) Schematic representation of the experimental setup used for testing the adaptive deep brain 
stimulation (aDBS) prototype in vitro. A plastic container with physiologic saline solution (9% 
NaCl) and with 4 Ag/AgCl electrodes (E1, E2, E3, E4), and a DBS electrode (E, Model 3389, 
Medtronic, USA). The waveform generator (Agilent 33220A) was connected to E1 and E3 to 
introduce sinusoidal waves. Monopolar cathodic DBS stimulation was delivered from contact 1 on 
E, and E2 serving as an anode, while E4 was used as a reference for recording. A standard 
amplifier measures the amplitude of the sinusoidal signal at the contacts of the DBS electrode. Data 
were acquired through a digitalization system (Micro1401) and processed by software. (b) Picture 
of the experimental setup in vitro. 
 
2.3.1.2 In vitro testing 
To evaluate the DBS stimulation artifact suppression, we connected the recording channel of the 
aDBS to contact 0 and 2, we collected 100 s of data both with DBS turned on and off with the 
cathode positioned on the contact 1; the waveform generator was switched off. The 100 s data were 
then divided into sweeps of 1 s, and on each sweep was performed an FFT obtaining 100 power 
spectral with 1 Hz resolution. We applied a two-way analysis of variance (ANOVA); one factor was 
the frequency (39 levels, from 2 Hz to 40 Hz; repeated measures), the other factor was the 
stimulation (on and off; independent measures) (Rossi et al., 2007). The same statistical test was 
then repeated for the power spectral normalized for the for the total power. The FFT output on the 
MCU was compared with the output of the FFT computed in Matlab.  
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To test the processing method previously described, and in particular, to test its ability track and 
distinguish levodopa-induced beta power changes, we provided as input to the saline solution real 
LFPs. This data sample came from a data set of a previous work (Marceglia et al., 2006). The 
amplitude of the LFPs at the DBS electrode was calibrated to match the real values.  
Finally, we used a sample feedback algorithm, based on a threshold ON-OFF logic, to test the 
ability of the device to change the stimulation parameters in response to beta power changes. The 
sample feedback algorithm was developed to change the stimulation amplitude from 3 to 0 when 
the control variable decreased under a certain value. This algorithm was tested on the real LFPs. We 
also studied the delay between the event detection (signal power crossing the threshold) and the 
amplitude update by applying to the saline solution a sinusoidal signal of 15 Hz. The amplitude was 
switched changed from 2 μVrms to 1 μVrms. 
2.3.1.3 In vivo testing 
At this stage, the objective of the testing in vivo was the validation of sensing and processing 
features of the prototype. The application of a specific feedback algorithm and the evaluation of its 
effectiveness fell outside of the scope of the following testing methods.  
We tested the aDBS prototype in one PD patient. The test took place two days after the surgery for 
the DBS electrode implant (Model 3389, Medtronic, USA), and it consisted of two phases.  
During the first, we assessed the stimulation contact, the stimulation parameters and the spectral 
features of the LFPs recorded at the baseline condition (overnight medication withdrawal).  
We choose the best contact to stimulate on the basis of the clinical outcomes of the surgery reported 
by the responsible neurologist. To select the neurophysiological parameters (peak frequency and 
frequency band), we recorded and analyzed LFP activity from both sides. As for the in vitro 
experiment, we recorded LFPs by means of standard amplifier for control (Model Grass ICP511, 
gain 80 dB, passband 1–100 Hz, notch ON), and recordings were done between all the contact pairs 
and using a skin Ag/AgCl electrode placed on the left shoulder as ground; the peak power of the 
LFP power was evaluated online (Spike 2, Cambridge Design, UK) and traced for each contact pair. 
By inferring the information about the best stimulation contacts and LFP recordings, we choose to 
stimulate from contact 1 and record from the contacts 0–2 of the right side. The simulation 
parameters were settled at 2.2 V, 130 Hz and 60 (amplitude, frequency, and pulse width). We 
selected the minimum voltage value that induced visible clinical effects, increased by 20%. 
Consistent with the literature (Ray et al., 2008; Kuhn et al., 2009), we selected a frequency band of 
5 Hz centered around the peak power. The device was programmed to extract and store the band 
power centered at 11 Hz +/− 2 Hz. Despite that this frequency band is the higher part of the alpha 
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band, it was reported that when the LFP activity is recorded with the patient in a resting condition it 
can then be associated with the beta band (Rossi et al., 2008). To discern whether the peak at 11 Hz 
was significant or not, we applied the method described in Rosa et al. (2011).  
During the second phase of the test, we ran the device programmed to store the band power values 
for all the testing times and switched ON the stimulation 250 s after starting the device. 
Because our goal was to test whether or not the prototype was able to the track levodopa-induced 
LFP power changes with the imposed transitory time (forgetting factor), we started the device when 
the patient was in the baseline condition and waited until the levodopa administration (occurring 
after 25 min) took effect. The patient’s condition transited from the OFFOFF (without medication 
and stimulation) to the OFFON (without medication and with stimulation) and finally to the ONON 
(with stimulation and medication). A neurologist monitored the clinical transitions of the patient. 
From the literature, it seems that all patients who manifest a significant power peak should undergo 
levodopa-induced modulation and the superimposition of the medicaton, and DBS should not have 
an additive effect on beta oscillatory activity (Giannicola et al., 2010).  
For the entire session, the LFPs were externalized from the aDBS prototype by connecting the 
analog output to the standard amplifier (see Section 3.1.2). We computed the time-frequency 
analysis of the raw data offline (Matlab) to check the temporal correspondence of the MCU real 
time analysis and the absence of the stimulation artifact in the analog pass band. Three data 
segments corresponding to the three clinical conditions were extracted from the raw data, and the 
normalized spectral power was computed for each condition with the Welch method (non-
overlapping 1 s Hanning windows).   
After the device was stopped, we downloaded the band power values stored during the entire test 
and applied a change point analysis to ensure that changes in the were not random, but related to 
clinical state transitions. We performed the change point analysis with a percentage time resolution 
of 3.3% (Rosa et al., 2010); this analysis lead to time windows of 126 s, consistent with the choice 
of the time constant (50 s). Fig. 2.3 shows the experimental set up in vivo. 
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Figure 2.3 In vivo experimental setup 
(a) Schematic representation of the experimental setup used for testing the adaptive deep brain 
stimulation (aDBS) prototype in vivo. The DBS electrode E (Model3389) externalization is 
connected with the aDBS prototype. Monopolar cathodic DBS is delivered from contact 1 
on E to the anode E1, and E2 serves as a reference. The local field potentials (LFPs) are 
recorded differentially from contacts 0-2 on E and E2, serving as reference. A standard 
amplifier measures the amplitude of the LFPs at the contacts of the DBS electrode. Data 
were acquired through a digitalization system (Micro1401) and processed by software 
(Matlab). (b) Picture of the experimental setup in vivo.  
 
2.4 Results 
2.4.1 In vitro results 
The pass band between 2 Hz and 40 Hz was artifact free, the stimulation did not introduce 
unwanted harmonics; however, the total mean spectral power was higher during DBS (two-way 
ANOVA; main factor frequency and main factor stimulation: p < 0.05, interaction factor p = 0.56). 
To confirm the results, we averaged the spectral power over the 100 sweeps and visually inspected 
the mean spectral power in the OFF and ON stimulation condition. The same statistical test was 
done on the power spectral normalized for the total power and showed that the operation of 
normalization compensated the effect of stimulation (main factor frequency: p < 0.05; main factor 
stimulation: p < 0.53; interaction factor p = 0.61). No difference was found between the FFT output 
obtained on the MCU and in Matlab (Fig. 2.4). 
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Figure 2.4 Comparison between online and offline fast Fourier transform (FFT) output. 
The visual inspection of the time frequency of the LFPs data confirmed that during the testing 
session with real LFPs, the DBS, when switched ON, did not alter the content of the spectral power 
in the band pass with unwanted harmonics (Fig. 2.5a). After 50 s (time constant) the value of the 
beta power extracted online approached the 36.8% of the transitory between the mean beta power 
values representing the OFFON and the OFFOFF states (Fig. 2.5b).    
When the beta power crossed an arbitrary predefined threshold value, the device switched off the 
stimulation output (Fig. 2.5c). The latency between the event detection and the voltage output 
update was 340 ms, the time needed to compute the processing of 1 s of data acquired at a 256 Hz 
sampling frequency (Fig. 2.6)  
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Figure 2.5 In vitro testing 
 (a) Spectral power time course of the local field potential (LFP) signal analogically externalized 
from adaptive deep brain stimulation (aDBS) before analog-to-digital converter (ADC) conversion. 
The spectral power time course in the pass band was computed offline in Matlab using the same 
algorithm running on the aDBS MCU. The spectral power values are normalized for the max and 
expressed in arbitrary units (AU). The MED OFF (without medication) and the MED ON (with 
medication) clinical states are separated by a dotted line. (b) Changes in the LFP signal power in 
the 10–16 Hz band memorized on the aDBS prototype. The selected transitory time was respected: 
the power of the selected band approached 36.8% of the total variation between the mean value in 
the MED OFF and MED ON condition. (c) Stimulation output changed from 3 V to 0 V when the 
band power crossed the threshold indicated by the blue dotted line. 
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Figure 2.6 Functioning of the switching algorithm 
Fig. 2.6. Functioning of the switching algorithm. An oscilloscope (Infiniivision X-series, Agilent 
Technologies, USA) was used to display the sinusoidal signal at 15 Hz (green) given as an input to 
the adaptive deep brain stimulation (aDBS) prototype and its stimulation voltage output (violet). 
The oscilloscope probe was placed on the electrode E1 and E3 to record the sinusoidal signal and 
on the electrode E4 and the stimulation contact of the DBS electrode (E) to record the stimulation 
(see Fig. 2.2a). The amplitude of the sinusoidal signal changed from 2 𝜇Vrms to 1 𝜇Vrms during 
the second epoch. The processing of each epoch takes place during the following epoch. On the 
bottom, the scheme represents the functioning of the algorithm. The normalized power spectral 
density (PSD) (arbitrary unit [AU]) as soon as the epoch is acquired. When the detected power 
crosses the threshold (red dotted line) the system changes the stimulation voltage. The time from 
epoch acquisition to stimulation update is 340 ms.  
 
2.4.2 In vivo results 
The power spectral in the three clinical conditions (OFFOFF, OFFON, ONON) was rebuilt offline 
showing that the analog front-end detected the beta peak when not modulated (Fig. 2.7a). 
The change point analysis, with confidence boundaries around 99% found the first change point at 
129 s after the device turned ON the stimulation, while the second was 63 s after the neurologist 
confirmed the ONON condition. The delays in the detection of the changes were consistent with the 
choice of the forgetting factor (150 s to reach the 95% of the total transition between changes). 
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Figure 2.7 Invivo testing 
 (a) Comparison between the power spectral density (PSD) in OFFOFF, OFFON, ONON states. (b) 
In vivo test model. After 250 s, the deep brain stimulation (DBS) was turned ON, and levodopa was 
administered after 1500 s. The individual patient’s metabolism influenced the duration of the test 
and justifies the difference in the durations of the three conditions. (b) Spectral power time course 
of the local field potential (LFP) signal analogically externalized from adaptive deep brain 
stimulation (aDBS) before analog-to-digital converter (ADC) conversion. The spectral power time 
course in the pass band was computed offline in Matlab using the same algorithm running on the 
aDBS MCU. The spectral power values are normalized for the max and expressed in arbitrary units 
(AU). The clinical states are separated by a dotted line. (c) Changes in the LFP signal power in the 
9–13 Hz band recorded on the aDBS prototype. The selected transitory time was respected: 
different gray tonalities indicate the change points computed offline through change point analysis. 
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3 Adaptive deep brain stimulation vs conventional deep 
brain stimulation: A proof of concept study 
3.1 Introduction 
Deep brain stimulation of the STN is nowadays an established and effective treatment for PD 
(Benabid et al., 2009; Castrioto et al., 2013; Deushl et al., 2006). However, conventional deep brain 
stimulation (cDBS) is limited in the long-term in that it can only partially control clinical 
fluctuations (Rodriguez-Oroz et al., 2012). Hence, as clinical fluctuations occur, stimulation can be 
unnecessary in certain periods and insufficient in others. Additionally, because the stimulation may 
contribute to the development of long-term complications (Rodriguez-Oroz et al., 2012), strategies 
that minimize stimulation application and intensity may also produce superior long-term outcomes. 
Reducing stimulation according to the effects of antiparkinsonian drug treatment and the 
corresponding clinical fluctuations can prevent transient summation of DBS and pharmacological 
therapy. Because specific clinical signs of PD are correlated with increased beta band LFP 
oscillations in the STN and, conversely, since beta band LFP power is reduced by levodopa (Ray et 
al., 2008; Kuhn et al., 2009) and correlates with motor improvements, we focused on designing an 
adaptive strategy based on beta power, aiming to reduce stimulation during pharmacological 
treatments to provide a proof of concept for the technical and clinical functioning. This chapter 
discusses how we defined the feedback algorithm, the method to parameterize it, its application in 
an experimental design, and the technical and the clinical results, with a focus on methodology 
rather than clinical results.  
3.2 Feedback algorithm design 
Levodopa-induced beta power modulations and their correlation with the patients’ clinical state 
have been widely reported (Priori et al., 2004; Kuhn et al., 2006; Kuhn et al., 2009; Ray et al., 
2008). Priori et al. (2004) studied the distinct frequency bands power changes under the effect of 
different pharmacological treatments: levodopa, apomorphine (a dopamine receptor agonist), and 
orphenadrine (an anticholinergic drug). Both levodopa and apomorphine (which act on the 
dopaminergic system) precipitated a power decrease in the beta band, while orphenadrine (which 
acts on the cholinergic system) induced a power increase. This study measured and tested the 
difference of logarithmic power before and after the pharmacological treatments, and no clinical 
correlations were reported. Similar results have been obtained by Kuhn et al. (2006), who reported 
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that after dopaminergic medication there is a decrease of band power centered on the peak found in 
the 8–35 Hz range, thus including alpha and beta oscillations, correlated with the motor 
improvement of the patient’s motor state. They found that the percentage change in the beta power 
[(beta power before medication – beta power after medication) / (beta power before medication) 
*100], correlated linearly with the percentage change of the clinical state measured on the Unified 
Parkinson’s Disease Rating Scale – Motion Scale (UPDRS III). The UPDRS III is a standard rating 
scale used by clinicians to evaluate the degree of the disease’s symptoms. The correlation was 
defined for a single levodopa administration cycle over a population of patients. Interestingly, the 
absolute UPDRS III score and the absolute beta power did not show any correlations. Based on 
these results, we inferred a feedback algorithm aimed to decrease the stimulation amplitude 
following levodopa-induced beta power fluctuations. 
We assumed as valid the linear correlation between the percentage power change and the 
percentage clinical change before and after levodopa administration, ideally expressed as follows:   
𝑈𝑃𝐷𝑅𝑆 𝑂𝐹𝐹−𝑈𝑃𝐷𝑅𝑆
𝑈𝑃𝐷𝑅𝑆 𝑂𝐹𝐹
= 𝑘1
𝑃𝛽𝑂𝐹𝐹 −𝑃𝛽
𝑃𝛽𝑂𝐹𝐹
+ 𝑘2 (1) 
where 𝑈𝑃𝐷𝑅𝑆 𝑂𝐹𝐹 is the clinical score at the “baseline” condition, 𝑈𝑃𝐷𝑅𝑆 is the actual clinical 
score, 𝑃𝛽𝑂𝐹𝐹 is the power of the band centered on the peak (it may include also alpha oscillations), 
𝑃𝛽 is the power of the band centered on the peak, and 𝑘1 and 𝑘2 are generic constants which define 
the linearity rule. This equation does not imply any causal relationships but assumes the beta power 
as a descriptor of the actual patient’s clinical state.  
We then assumed, as a rule of thumb, that a given clinical score is associate with a determined 
stimulation amplitude, and that a percentage change in the clinical score requires a correspondent 
percentage change in the stimulation amplitude:   
 𝑉𝑂𝐹𝐹−𝑉
𝑉𝑂𝐹𝐹
= 𝑘3
𝑈𝑃𝐷𝑅𝑆 𝑂𝐹𝐹 −𝑈𝑃𝐷𝑅𝑆
𝑈𝑃𝐷𝑅𝑆 𝑂𝐹𝐹
+ 𝑘4  (2) 
where 𝑉𝑂𝐹𝐹 is the stimulation voltage needed to treat the “baseline” clinical state, 𝑉 is the actual 
stimulation amplitude, and 𝑘3 and 𝑘4 are generic constants. By substituting the terms 𝐾𝑎 =  𝑘3𝑘1 
and 𝐾𝑏 =  𝑘3𝑘2 + 𝑘4, (3)  in (1) and (2), (3) is obtained.  
𝑉 = 𝐾𝑎
𝑃𝛽𝑂𝐹𝐹 − 𝑃𝛽
𝑃𝛽𝑂𝐹𝐹
∗ 𝑉𝑂𝐹𝐹 + (1 − 𝐾𝑏) ∗ 𝑉𝑂𝐹𝐹  (3) 
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3.2.1 Parametrization method 
Parametrization definition. To be applied, (3) needs to be parametrized for patient-specific 
characteristics. Because the derivation of the adaptive rule started from a linear correlation 
determined in a population of patients, when moving to the single patient the parameter, 𝑃𝛽𝑂𝐹𝐹 is a 
constant, so the stimulation amplitude (and the clinical state) becomes a function of 𝑃𝛽 and not of 
the percentage change. To determine that the parameters of the adaptive rule are 𝑃𝛽𝑂𝐹𝐹, 𝑉𝑂𝐹𝐹, 
𝐾𝑎, 𝐾𝑏, it is necessary to empirically associate the values of at least two clinical scores, the 
correspondent beta power values, and stimulation voltage (see Fig. 3.1). 
 
Figure 3.1 Schematic representation of the parametrization problem 
The 𝑆𝑐𝑜𝑟𝑒1 corresponds to the baseline condition, 𝑈𝑃𝐷𝑅𝑆 𝑂𝐹𝐹, meaning that the 𝑉1 is actually 
𝑉𝑂𝐹𝐹 and 𝑃𝛽
1 is 𝑃𝛽𝑂𝐹𝐹. The remaining parameters are 𝐾𝑎 and 𝐾𝑏, which determine, respectively, the 
gain and the offset and can be calculated if 𝑉2 and 𝑃𝛽
2 are known. We defined an empirical process 
to determine 𝑉2 𝑎𝑛𝑑 𝑃𝛽
2. 
Empirical parameterization method. In the clinical practice, the titration of the stimulation 
parameters is today an empirical process performed by a neurologist during follow-up visits. 
Various workflows have been proposed to optimize the stimulation parameters (i.e. Volkmann et 
al., 2002) and mainly focus on the adjustment of the amplitude, even if the frequency seems to have 
a relevant role in symptoms management (Fasano et al., 2014). The pulse width is generally kept as 
low as possible (lower to 60 us) (Fasano et al., 2014). The effective voltage amplitude to treat the 
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patient at the baseline condition is chosen on the base of the neurologist’s selection criteria. The 
𝑉𝑂𝐹𝐹 is thus set equal to the effective voltage amplitude. Under the baseline condition, the LFPs of 
the patient are recorded and the beta band power is extracted. To drive a change in the clinical state, 
a dopaminergic pharmacological treatment is administered, and, after its effect is revealed by a 
neurologist, the beta band power is calculated and associated with the parameter 𝑃𝛽
2, an arbitrary 𝑉2 
value lower than 𝑉1. A specific realization of the parametrization method is described in Section 
3.3.3. 
3.3 Proof of concept study  
3.3.1 Methods 
3.3.1.1 Patient recruitment 
We enrolled patients with advanced PD who underwent neurosurgery for STN DBS electrode 
implantation. Patient recruitment was based on clinical and neurophysiological assessments. We 
included all patients who did not experience any surgical complications. The neurophysiological 
inclusion criterion was the presence of a significant peak in beta band (12–35 Hz) following the 
method proposed in (Rosa et al., 2010).  
3.3.1.2 Study design 
After DBS surgery, the electrode leads were externalized to enable recording of LFPs before the 
electrodes were connected to the IPG a few days later. The experimental protocol included three 
sessions (one per day) that took place from day 5 through day 7, after the electrode implantation 
surgery. During the first session, experimenters collected LFP recordings to identify beta band 
frequencies and to adjust the adaptive deep brain stimulation (aDBS) algorithm accordingly for 
each patient (see “parametrization”). During the second and the third sessions, we administered the 
two DBS treatments to patients through the external dual prototype (one treatment per day). The 
stimulation lasted at least two hours.  
Patients were randomly assigned to first receive either cDBS or aDBS. We used computer-
generated randomization assignment according to the order of recruitment so that a comparable 
numbers of patients were treated with aDBS and cDBS. The randomization sequence was generated 
by the experimenter (the same person as for the aDBS setup). The patient and the neurologist 
directly involved in the scoring were blinded to the DBS type; only the experimenter was aware of 
the type of stimulation.  
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3.3.1.3 Experimental procedure 
The external prototype was placed in a pouch worn by the patient at the waist level, which allowed 
the patient to move freely. The device was connected to the electrode selected for the best recording 
and stimulation.  
Both aDBS and cDBS were delivered unilaterally in the hemisphere in which the recorded LFPs 
showed the highest beta band peak. Accordingly, we recorded the feedback signal for the aDBS 
from the electrode contact pair that exhibited the highest beta peak and used the contact located 
between these contacts for stimulation (the same for aDBS and cDBS sessions). At the time of the 
experiment, levodopa was the only pharmacological treatment administered to the patients who 
arrived at the surgery after three to four weeks of washout from all their antiparkinsonian 
medication, according to the current clinical procedure. 
 
Figure 3.2 Experimental sessions 
After beta band identification, we selected the best recording and stimulation configuration for 
optimal aDBS. We determined the hemisphere and electrode contact pairs (0-2; 0-3; 1-3) that 
exhibited the highest beta peak. If a patient manifested a similar beta peak from both STN signals, 
we chose the side contralateral to that associated with disease onset in that patient. The stimulation 
contact was located between the two contacts selected for recording. We then identified the 
effective stimulation amplitude for each patient. To this end, we delivered a monopolar stimulation 
 
 
 
36 
 
using the prototype in cDBS mode at 130 Hz with a 60 μs pulse and progressively increased the 
intensity by 0.5 V every 3–4 min until the first stimulation-induced adverse effects appeared. The 
effective stimulation amplitude was defined as the lowest stimulation intensity that induced at least 
a 60% improvement in upper limb rigidity on the side contralateral to the stimulation site, without 
adverse effects.  
Then, to establish the reference beta band power values 𝑃𝛽𝑂𝐹𝐹 and 𝑃𝛽
2, we connected the prototype 
through the input and output channels to the previously selected electrodes and programmed it to do 
as follows: record LFPs for about 20 min (baseline clinical condition) before switching on the 
stimulation at the effective amplitude, to record LFPs for a further 20 min (stimON/medOFF 
condition) and to continue to record LFPs while administering levodopa (the patient’s usual 
antiparkinsonian medication with the treatment dose increased by 50%) and waiting for the drug to 
achieve its clinical effect (stimON/medON). We then analyzed LFP beta activity offline to extract 
the reference values of beta band power in the stimOFF/medOFF and stimON/medON, 
respectively, 𝑃𝛽𝑂𝐹𝐹 and 𝑃𝛽
2. Hereafter we refer to the 𝑃𝛽
2 value as 𝑃𝛽𝑂𝑁. 
We used the specific beta band boundaries, the effective stimulation amplitude, and the reference 
values of beta band power for each patient to set up a personalized aDBS algorithm. Because our 
aim was to reduce the stimulation voltage to a value close to zero, we set 𝑉2 = 0. Under these 
conditions, and by substituting in (3) the terms “𝑃𝛽𝑂𝐹𝐹  − 𝑃𝛽” with “𝑃𝛽𝑂𝐹𝐹  − 𝑃𝛽𝑂𝑁 −  𝑃𝛽 + 𝑃𝛽𝑂𝑁,” 
(3) is reduced to (4): 
𝑉 =
𝑃𝛽−𝑃𝛽𝑂𝑁
𝑃𝛽𝑂𝐹𝐹−𝑃𝛽𝑂𝑁
𝑉𝑂𝐹𝐹  (4) 
 
This adaptive rule is applied only for values of 𝑃𝛽𝑂𝑁 < 𝑃𝛽 < 𝑃𝛽𝑂𝐹𝐹, for 𝑃𝛽 > 𝑃𝛽𝑂𝐹𝐹  𝑡ℎ𝑎𝑛 𝑉 = 
𝑉𝑂𝐹𝐹, 𝑃𝛽 < 𝑃𝛽𝑂𝑁 𝑡ℎ𝑎𝑛 𝑉 = 0. 
In the aDBS mode, the device was therefore programmed to deliver a 130 Hz stimulation with a 
60 µs pulse and an amplitude that linearly changed, according to beta power recorded, between 0 V 
and the effective stimulation amplitude calculated for each patient. Conversely, in the cDBS mode, 
the device delivered a 130 Hz stimulation with a 60 µs pulse at the effective stimulation amplitude. 
Thus, in the aDBS mode, the stimulation amplitude could not exceed the effective stimulation 
amplitude delivered continuously in the cDBS mode. The prototype recorded the stimulation 
amplitude delivered during the aDBS session. 
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3.3.1.4 Technical and clinical outcomes 
The technical outcomes encompass the functioning of the aDBS device and its energy efficiency. 
The former included the assessment of the efficacy of DBS stimulation alone, in both modalities 
(aDBS and cDBS). To make this assessment, we calculated the UPDRS III improvement in the 
stimON/medOFF condition with the stimOFF/medOFF condition. It also included the assessment of 
its ability of the aDBS device algorithm to follow beta changes by comparing the stimulation 
amplitude delivered during OFF and ON Med. 
The energy efficiency of the prototype in the aDBS and cDBS modes was evaluated using the total 
electrical energy delivered (TEED) per unit (Koss et al., 2011) with a reference impedance of 
0.5 kΩ. 
The clinical outcomes were the aDBS clinical effect compared to cDBS evaluated through the 
UPDRS III and the UDysRS scores when the patient had both DBS and medication 
(stimON/medON condition). 
3.3.1.5 Statistical analysis 
We first verified that clinical scale scores (UPDRS III and the Unified Dyskinesia Rating Scale 
[UDysRS III-IV]) were normally distributed through the single-sample Shapiro-Wilk test 
(p > 0.05); therefore parametric statistical analyses were performed.  
We then calculated the stimulation-induced improvements for the UPDRS III clinical scale in the 
stimON/medON condition compared to the baseline condition (stimOFF/medOFF), and we 
compared the UDysRS scores during cDBS and aDBS in stimON/medON. We used a repeated 
measures one-way ANOVA for both the UPDRS III and the UDysRS scores. 
To verify the effectiveness of the device delivering dual-mode stimulation (aDBS and cDBS), we 
compared the UPDRS III at the baseline and at the stimON/medOFF condition (one-way ANOVA). 
As an adjunctive analysis on the effect of DBS alone (stimON/medOFF condition), we examined 
the change in UPDRS III items on the side contralateral to stimulation.  
Then, to study the other secondary outcomes (functioning of the aDBS algorithm), we used a 
repeated measures one-way ANOVA to compare the mean amplitude delivered by the device 
during the OFF and ON Med periods. 
We used a repeated measures one-way ANOVA to compare TEED in the aDBS and cDBS modes. 
Power saving was calculated as the mean percentage of change in TEED in the aDBS compared to 
the cDBS modes.  
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Statistical analyses were performed using the Matlab software (The MathWorks, Natick, USA). 
Differences were considered significant at p < 0.05. Throughout the text, values are given as mean 
± standard deviation (SD). 
3.4 Results  
We found that 14 patients out of 17 met the neurophysiological inclusion criterion displaying beta 
activity. Fourteen PD patients (nine men and five women; age 56.4 ± 8.4 years, disease duration 
12.6 ± 5.3 years) were enrolled. Of them, four withdrew from the study: three patients left the study 
during the second experimental session because of intolerability to medication withdrawal, and 
Patient 3 left the study during the third experimental session because of fatigue. Ten patients 
completed all of the experimental sessions: four patients first received aDBS and six patients first 
received cDBS. Consistent with recent findings (Quinn et al., 2015), we observed that the 100% of 
AR patients and the 62.5% of TD patients showed beta band oscillations. Moreover, women are 
more likely to show beta activity than men (100% vs 70%), and no significant differences were 
found for age and disease duration. 
3.4.1 Technical results 
The stimulation voltage changed according to the changes in beta power. The beta band power 
decreased when patients completed the transition from the med OFF to the med ON state. 
Accordingly, the stimulation amplitude linearly decreased from the med OFF to the med ON state 
(Fig. 3.3b). The stimulation amplitude significantly decreased from the med OFF to the med ON 
conditions in all cases (med OFF vs med ON: 2.1 ± 1.2 V vs 0.8 ± 0.9 V; p = 0.007). The mean 
TEED with aDBS (44.6 ± 47.9 µW) was significantly less than with cDBS (158.7 ± 69.7 µW; 
p = 0.0005) (Fig. 3.3) with an average power saving value of 73.6 ± 22.9% in aDBS compared with 
cDBS. 
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Figure 3.3 (a) Stimulation amplitude course in one patient, (b) total electrical energy delivered 
(TEED) comparison  
3.4.2 Clinical results 
We first assessed the ability of the device to deliver an effective stimulation during both aDBS and 
cDBS without levodopa, according to the decrease of UPDRS III score: the UPDRS III score 
significantly decreased from the stimOFF/medOFF condition to stimON/medOFF condition during 
cDBS (36.6 ± 16.2 vs 30.8 ± 14.3; p = 0.03) and during aDBS (37 ± 16.8 vs 33.1 ± 16.4; p = 0.002) 
sessions (Fig. 3.4). 
The clinical scores were not significantly different between the two treatment days at the baseline 
(stimOFF/medOFF) (UPDRS III: aDBS vs cDBS: 37 ± 16.8 vs 36.6 ± 16.2; p > 0.05).  
When the patient was under the effect of both levodopa and DBS, we observed a similar 
improvement in global motor symptoms due to aDBS and cDBS combined with levodopa, but 
aDBS had a remarkable lowering effect on dyskinesias compared to cDBS. In fact, comparing the 
stimulation-induced effect, the one-way ANOVA showed that aDBS and cDBS induced similar 
improvements in UPDRS III score when combined with levodopa in stimON/medON conditions 
(UPDRS III, aDBS vs cDBS: −46.1 ± 10.5% vs −40.1 ± 17.5%; p > 0.05, Fig. 3.5a).  
Conversely, aDBS and cDBS differentially modulated in terms of the UDysRS score. During the 
aDBS session, patients experienced significantly less dyskinesias, compared with in the cDBS 
session, in the stimON/medON conditions (aDBS vs cDBS: 11.6 ± 69 vs 15.0 ± 8.7; p = 0.01, Fig. 
3.5b) 
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Figure 3.4 UPDRS III score under conventional deep brain stimulation (cDBS) and adaptive DBS 
(aDBS) 
 
Figure 3.5. (a) UPDRS III score percentage improvement, adaptive deep brain stimulation (aDBS) 
vs conventional DBS (cDBS); (b) UDysRS score improvement, aDBS vs cDBS. 
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4 Exploring local field potential-based adaptive deep 
brain stimulation feasibility: Eight hours of 
monitoring 
4.1 Rationale for the study and objectives 
The proof of concept study reported in the previous chapter showed that under defined and 
controlled circumstances, adaptive deep brain stimulation (aDBS) is as effective as cDBS and 
avoids unwanted side effects such as dyskinesias. The same results may be not valid during a longer 
period of time and during a common daily medication administration (not increased of the 50%). In 
particular, to our knowledge, no one has explored the correlation of beta oscillations with the 
patient clinical state during daily activities and for a long period of time. All the studies that 
investigated LFP response to levodopa have been restricted to a single administration (Priori et al., 
2004; Ray et al., 2008; Kuhn et al., 2009). A lack of correlation would prevent the feasibility of 
LFP-based aDBS. We therefore designed a two-day experimental session. During the first day, we 
monitored the beta band power changes and the clinical state of the patient; during the second day, 
we also applied aDBS to test whether or not it was possible to follow clinical fluctuations, to 
explore clinical results and to propose future steps to improve the methodology.   
4.2 Methods 
4.2.1 Patients’ inclusion criteria 
All patients effected by PD who had undergone to DBS electrode implant in the STN with respect 
to the surgery eligibility criteria (L.I.M.P.E.) not showing complications after surgery were included 
as candidates for the study. The experimental protocol took place after the surgery for electrode 
placement and the surgery for the implant of the pulse generator. Deep brain stimulation electrodes 
were externalized to allow for stimulation and recording. Patients not showing significant LFP 
activity in the beta band were excluded (see Section 4.2.3). Each patient underwent to two 
experimental sessions the fifth and the sixth day after the surgery for the electrode implant to ensure 
impedance stability (Rosa et al. 2010). Each experimental session lasted seven to eight hours and 
began after 12 hr of medication withdrawal.  
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4.2.2 Experimental protocol 
The experimental protocol was composed of two sessions (i.e. two days) (Fig. 4.1). 
 
Figure 4.1 Experimental protocol 
First session 
Local field potential recordings at rest, contact selection, and band definition. We recorded the 
LFPs at rest from both the hemispheres in bipolar configuration from the contact pairs (0-1,0-3, 1-3) 
of the externalized DBS electrodes (Model 3389, Medtronic). An Ag-AgCl surface electrode was 
positioned on the right shoulder as a reference. The LFPs were recorded with an instrumental 
amplifier (Model Grass ICP511, gain 80 dB, passband 3–30 Hz, notch ON) and digitalized (CED 
Micro-1401, Cambridge Design, UK). The LFPs were sampled at 256 Hz and their PSDs were 
visualized online by means of the software Spike 2 (Spike 2, Cambridge Design, UK), using a 
Hanning window of 1 s averaged over 50 s to 60 s. Based on intra-surgery stimulation tests we 
choose the contact pair allowing for stimulation at an effective contact and showing a detectable 
beta peak. The band was selected at +/−2 Hz around the peak frequency (Ray et al., 2008; Kuhn et 
al., 2009). Electrode impedances were acquired at 30 Hz using an impedance meter (Model EZM 4; 
Grass, USA). 
Neurophysiological monitoring. The external portable device (see Chapter 2) was connected to the 
selected contact and shoulder reference to record LFPs during the day for up to eight hours. The 
device stored in not volatile memory a value of the power of the selected band every 2 s. In 
addition, the 2.4 GHz RF interface was programmed to send the module of the FFT between 5 Hz 
and 30 Hz every second. The RF link on the device board covered a short range, allowing us to 
track the LFP data during daily activity occurring in the hospital room and not outside. The device 
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was connected to the belt and allocated in a pouch, thus allowing the patient to carry out daily 
activities. A wearable accelerometer was placed on the arm contralateral to the stimulation to 
collect kinematic data. The LFPs and acceleration data were stored in real time on the PC by means 
of a custom script written in Matlab for reading data arriving at a USB access point (Fig. 4.2).   
 
Figure 4.2 Data collection 
Pharmacological treatment and clinical monitoring. The clinicians subministered to the patient a 
levodopa therapy similar to the regular treatment the patient had before the operation, but decreased 
the dose to accomplish the state of the patient improved by the “stun” effect of the surgery for the 
DBS electrode implant. If the patient was used to taking dopamine agonists, these were substituted 
with levodopa therapy when possible. In cases that such a substitution was not possible, the patient 
was included in the study anyway under the hypothesis that the dopamine agonist has the same 
effect as levodopa on LFPs spectral content (Priori et al., 2004). The clinical state of the patients 
were monitored by an unblinded neurologist who annotated on a clinical diary the time and the 
dosage of the levodopa therapy and the state of the patient. The clinical state of the patients were 
evaluated in the OFF condition, during the peak dose (Med ON) and at the end of the dose before 
the successive pharmacological assumption (Med OFF), with constant delays when possible. For 
each evaluation, the neurologist gave scores on the following rating scales: UPDRS III and 
UDysRS. At least two pharmacological cycles for each patient have been monitored (Fig. 4.1). A 
clinical diary was also filled by the patient every 30 min as qualitative support in the clinical 
monitoring process, but its contents do not appear in the following the analysis.  
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Second session 
Tuning the stimulation threshold. With the use of our external device, the stimulation voltage was 
increased in steps of 0.5 V until the appearance of side effects. At each step, a neurologist evaluated 
the contralateral motor improvement. The voltage threshold was chosen as the value which 
provided the greatest clinical effects without exacerbating side effects. 
Setting and Testing aDBS. The aDBS device was programmed as described in Section 3.3. The 
stimulation voltage changed linearly between the threshold voltage value and zero. The beta band 
analysis was performed in real time as described in Chapter 2, and the stimulation voltage was 
adapted proportionally on the basis of the power range given by the value of the beta power in Med 
OFF condition (at rest) and the value in Med ON condition.  
Neurophysiological and clinical monitoring. The neurophysiological and clinical monitoring were 
done following the same methods used during the first session.  
Results obtained during the two days of the experimental session were excluded if the offline 
analysis of rest LFPs failed to show a significant oscillation.  
4.2.3 Signal processing and statistical analysis  
Local field potentials analysis  
Local field potentials of nine patients were recorded from the 18 STNs five days after the implant of 
DBS electrodes. The patients were 12 hr without medication at the time of the recordings. The LFPs 
were recorded through the Grass amplifier (bandwidth 1–100 Hz, gain 80 db, notch ON) and 
sampled at 256 Hz. Signals were filtered offline between 2 and 50 Hz in forward and backward 
directions (“filtfilt” Matlab) to avoid any phase distortions. The minimum common length of the 
data for all patients was 50 s. To separate the background noise to the oscillation component, we 
applied the coarse-grained FFT analysis as proposed in (He et al., 2010; He et al., 2014). This 
method centers on the hypothesis that the background noise is a “scale free” process having a power 
spectrum following the rule 1/𝑓𝛼 . Under this assumption, the background neural noise is not given 
by the averaging of transient, non-stationary oscillations, but is the result of arrhythmic activity on a 
fractal domain.   
The coarse-grained FFT analysis, therefore, provides three spectral estimations, Praw (power 
spectrum of the raw data), Posc (power spectrum of the oscillatory), and Pfractal (power spectrum 
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of the "scale-free" background noise). A peak in the Praw component was considered independent 
of the background noise when a separation of the confidence interval (95%) occurred. 
To test the independence between impedances of the recording electrodes and the amplitude of the 
alpha or beta peak we calculated the Pearson coefficient.  
Local field potentials and clinical state correlation 
Only the neurophysiological data of patients showing a significant beta oscillation were included in 
this study. For these patients, the band power time course was analyzed offline. The band power 
was interpolated to have a value every second and then smoothed at an average of 10 min average. 
In correspondence of the clinical evaluations, the mean value of the band power was extracted. The 
absolute values of the band power and the percentage change with respect to the OFF Med state 
(band power OFF Med – band power current state / band power OFF Med state) were then linearly 
correlated to the absolute UPDRS III percentage changes from the OFF Med state (UPDRSIII OFF 
Med – UPDRSIII OFF current state/ UPDRSIII OFF OFF Med state) (here OFF Med refers to the 
first OFF Med state obtained after 12 hr of medication withdrawal). We tested the normality 
distribution of the data with the single sample Shapiro-Will test (p < 0.05), and we then applied 
parametrical statistics.  
Clinical data 
We collected the total UPDRS III and the UDysRS (part 3 and 4) five times during the whole 
experimental session: once at baseline, twice when the patient was in peak dose (Med ON), and 
twice when the effect of medication ended (Med OFF). We used these data to compare the clinical 
outcomes in the two days, and establish whether aDBS was effective. 
We used the percentage value at each time point for further analyses (V%t). We verified 
distribution normality through the single-sample Shapiro-Wilk test (p>0.05), to allow the use of 
parametric statistics. 
Three main factors could influence the values of clinical data: the day of the session (Day 1, no 
aDBS; Day 2, with aDBS); the medication condition (Peak dose, Med ON vs End dose, Med OFF); 
and the medication session (session 1, first morning dose; session 2, second daily dose). For this 
reason, we first run a three-way Analysis of Variance (ANOVA) with factors “therapy” (2 levels, 
Day 1 and Day 2), “condition” (2 levels, Med ON and Med OFF), and “session” (2 levels, Session 1 
and Session 2). When the three-way ANOVA showed a significant effect (p<0.05) for the factors 
“therapy” and “condition”, we proceeded applying a two-way ANOVA, splitting the dataset in two, 
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one grouping the Peak dose (Med ON) values and the other one grouping the End dose (Med OFF) 
values. In each group, we run a two-way ANOVA with factors “therapy” (2 levels, Day 1 and Day 
2), and “session” (2 levels, Session 1 and Session 2). A post-hoc Tukey’s HSD test was then 
applied (p<0.05). Values in the text are given as mean +/- SD. 
To be sure that the devices functioned correctly, we correlated the mean stimulation values at each 
clinical evaluation. Because the stimulation voltage was proportional to the beta power percentual 
change, we here correlated the clinical percent change with the stimulation value normalized for the 
specific threshold value of each patient and the multiplied by 100 to enable comparisons between 
patients. The energy efficiency of the prototype in the aDBS and cDBS modes was evaluated using 
the TEED per unit with a reference impedance of 0.5 kΩ. All the statistical analysis was computed 
in Matlab. 
 
4.3 Results 
4.3.1 Local field potentials analysis 
In a total of nine patients, we found distinct oscillatory activity in all nine (Fig. 4.3), and only one 
out of 9 was tremor dominant and showed a peak in the alpha band at 11 Hz (Fig. 4.3). The power 
of the peaks was not correlated with the value of the impedances (c = 0.15, p = 0.69) confirming 
previous findings (Rosa et al.2010). The mean peak power for these patients was 0.75 𝜇𝑉/√𝐻𝑧, 
consistently with data reported in Chapter 2.  
 
Figure 4.3 Power spectrum of raw local field potential LFPs data (red) and background noise 
(black) plus 95% confidence intervals (green and dot black lines respectively)  
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4.3.2 Local field potentials and clinical state correlation 
During both the first experimental session (no DBS) and during the second experimental session 
(aDBS), the band power correlated with the clinical motor state of the patients (r = 0.59, p < 0.001, 
no DBS; r = 0.58 p = 0.001, aDBS) (Fig. 4.4). For the first session, patient 5 was excluded from the 
correlation calculation because of an operative error at the end of the experimental session which 
caused the deletion of the band power values. For patient 2, we had only four clinical evaluations 
with the relative band power value because the fifth was done when there was no more memory 
space. Patient 8 was not included because the beta peak was not consistent between Day1 and Day2 
at rest state.   
 
Figure 4.4 %UPDRSIIIUPDRS III change to- %Beta Power change correlation 
 
The time-frequency spectrum collected over the RF was rebuilt offline and smoothed with a 10 min 
average window to improve the signal-to-noise ratio. Because of the short range RF link (4–5 m), 
some data are missed and interpolated offline. Only one patient out of six showed low-frequency 
oscillatory activity (Fig. 4.5), which alternated the beta oscillations in ON Med conditions. This 
behavior of low frequency has been recognized to correlate with levodopa-induced dyskinesias 
(Alonso-French et al., 2006).  
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Figure 4.5 Time-frequency - Patient 4 
4.3.3 Clinical data 
aDBS was effective in improving UPDRS III motor scores by almost 35% when the patient was 
OFF medication. In fact, the three-way ANOVA run on UPDRS III percentage changes from 
baseline showed that both the “therapy” (Day 1 vs Day 2) and the “condition” (Med OFF vs Med 
ON) had a significant effect (p=0.038 and p<0.001 respectively). This result allowed us to break up 
the data into two groups, Med OFF and Med ON. In the Med OFF condition, when the patient was 
at the end of the levodopa dose effect, only during Day 2, with aDBS ON, the patients experienced 
a significant improvement from baseline (two-way ANOVA factor “therapy” p=0.033, Day 1 vs 
Day 2: -9.8 +/- 25.8% vs -32.9 +/- 24.7%). There was no difference between the two sessions (two-
way ANOVA factor “session” p=0.55), nor between the two sessions in the two days (two-way 
ANOVA factor interaction “session” x “therapy” p= 0.67). Conversely, when patients were on peak 
dose (Med ON), the effect of levodopa was predominant on that of aDBS, and, in the two days, the 
UPDRS III improvement was similar (two-way ANOVA factor “therapy” p=0.43, Day 1 vs Day 2: 
-48.5 +/- 18.8% vs -55.1 +/- 22.0%). Again, there was no difference between the two sessions (two-
way ANOVA factor “session” p=0.60), nor between the two sessions in the two days (two-way 
ANOVA factor interaction “session” x “therapy” p= 0.72). 
The UDysRS remained unchanged in all conditions (three-way ANOVA factor “therapy” p=0.80, 
factor “condition” p=0.11, factor “session” p=0.40). 
The stimulation voltage correlated linearly with the percentage UPDRS III change (r = −0.51, 
p = 0.0004) (Fig. 4.6), and the correlation is negative because of the formulation of the adaptive 
rule. Assuming cDBS with a voltage equal to the max value of aDBS we would have reduced the 
TEED by 70%. 
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Figure 4.6 % UPDRS III change in Day 1 and Day2 in Med ON and Med OFF state  
 
Figure 4.7 Stimulation Amplitude value - to % UPDRS III change 
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5 Low Power Algorithm design 
5.1 System Requirements 
Implantable and wearable medical devices often require the processing of biological signals in real 
time for diagnostic or therapeutic purposes. Mathematical operations needed to process the incoming 
information are often expensive in terms of computational and power consumption. Implantable 
devices, more than wearable, have very restrictive constraints in terms of size and power budget. The 
battery types commercially available are classified as primary (not- rechargeable) or secondary 
battery (rechargeable). The first type can provide up to 6000 mA/h and the second type 200 mA/h, 
allowing more than 20,000 recharging cycles (Quallion LLC, USA). The lifetime of conventional 
implantable devices for DBS depends on the stimulation parameters settings (amplitude, frequency 
and pulse width) (Volkmann et al., 2002), and the power consumption of the other parts of the systems 
have a lower effect on the battery life. Based on typical values used in the clinical practice, the average 
power consumption is 250 µW (Avestruz et al., 2008). However, to include the possibility to acquire 
and process the signal, it is necessary to add the consumption for recording (analog front end), 
digitalization (i.e. ADC) and digital signal processing. In this chapter, we focus on the current and 
power needed for digital signal processing, in particular for executing one real-FFT of 1024 samples 
every second.     
5.2 Methods 
5.2.1 Low-power algorithm design workflow 
The design of a low-power algorithm requires a parallel analysis of the mathematical and 
computational complexity of the problem and of the specifications of the digital platform 
(Raghunathan et al., 2011). A few steps are needed to bridge the gap between the offline algorithm 
design and its implementation; here we propose the workflow model shown in Fig. 5.1.   
 
 
 
51 
 
 
 
Figure 5.1 Low-power algorithm design workflow 
5.2.2 Optimum algorithm and complexity reduction 
Signals collected during experimental sessions have been used to design the optimum algorithm and 
its complexity reduction (see Section 5.4.2). The basic operation of the project-specific application 
requires the implementation of a real FFT of 1024 samples each second. 
5.2.3 Benchmarking hardware architectures 
5.2.3.1 Number of instructions 
A few algorithms are available to implement the FFT in a discrete domain: radix-2, radix-4, split 
radix, fast Harley transform, and FFT (Balducci et al., 1997). The number of arithmetical operations 
changes with the type of algorithm; therefore, for simplicity, here we analyzed only the case of the 
radix-2 algorithm (Cooley & Tukey, 1965). 
The radix-2 algorithm can be implemented in two way: decimation in time (DIT) and decimation in 
frequency (DIF); for illustrative purposes, we here discuss the radix-2 DIT, but the methods are 
expandable for all the derivations. The scheme in Fig. 5.2 represents the radix-2 DIT 
implementation for eight complex samples (N = 8). 
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Figure 5.2 Radix 2 DIT fast Fourier transform (FFT) (Proakis & Manolakis 2007) 
The basic operation is called a “Butterfly” operation (Fig. 5.3). Each butterfly is done N/2 times for 
log2(N) stages. Each butterfly consists of one complex multiplication and two complex sums. 
Because each complex multiplication can be decomposed into four real multiplications and two 
additions, and a complex sum in two real additions, each butterfly results in a total of four 
multiplications and eight additions. Furthermore, to arithmetical, each butterfly requires also eight 
fetches operations (Table 5.1) (R. Meyer & K. Schwarz, 1990). 
 
Figure 5.3 Butterfly operation (Proakis & Manolakis 2007) 
 
 
Table 5.1 Number of instructions for one complex butterfly 
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N complex numbers can be represented by two vectors of N samples, one for the real part and one 
for the imaginary part. The factors “W” are named twiddle factors and are complex numbers 
representing the exponential terms of the discrete Fourier transform (DFT). The completion of one 
butterfly requires four load and four store operations for data and two load operations for twiddle 
factors (optional).  
The total number of instructions per butterfly is therefore 18, and if N = 1024 then the number of 
instructions for a complex radix-2 DIT FFT is 92,160. For instance, if each instruction is computed 
in one cycle, then for a clock frequency of 1 MHz, the operation is concluded in 0.09 s. Given the 
number of arithmetical operations and the type of instructions, the type of processor strongly 
impacts on the time and the power consumed for the computation (R. Meyer & K. Schwarz, 1990). 
5.2.3.2 Number of architectural resources and field-programmable gate arrays’ 
performances 
The choice of the hardware to implement the algorithm is mainly constrained by the power 
consumption. 
Digital signal processors (DSPs) are the best choice in terms of computational efficiency, but their 
current consumption is too high for implantable devices; on the other hand, ultra-low power 
microcontrollers are not suitable for real-time processing applications. However, the recent spread 
of the wearable and automotive sectors has pushed the industries to develop new solutions for low-
power processing. An example is the ultra-low power microcontroller MSP430FR5994 (Texas 
Instrument, Dallas, Texas, USA). This particular microcontroller includes a peripheral called low-
energy accelerator (LEA) for signal processing, which can perform typical processing operations 
(FIR, FFT) without calling the central processing unit (CPU), thus achieving lower power 
consumption and computational time.  
Custom solutions such as application-specific integrated circuits (ASICs) ensure high performance 
with concurrent low power consumption and low area; however, their development implies high 
costs, long time, and high complexity and risk. A trade-off solution is presented by field-
programmable gate arrays (FPGAs), which, in contrast, are reconfigurable, low cost, easier and 
faster to develop. These devices are in fact programmable with hardware description languages 
(HDLs) such as Verilog (VHDL). FPGAs consist of logic blocks including look-up tables (LUTs) 
connected to a multiplexer and to a flip flop; each LUT has four inputs, which configure Boolean 
functions. An FPGA has a routing architecture made of lines and switches in order to connect more 
LUTs or logic blocks and to create more complex functions. Compare to ASICs, the area and the 
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power consumption of FPGAs are higher. Here, we rely upon a review of the solution commercially 
available as proposed by De La Piedra and colleagues (De La Piedra et al., 2012), based on 
resources and static power consumption (Table 5.2, Table 5.3, and Table 5.4). 
 
Table 5.2 Xilinx field-programmable gate arrays (FPGAs) (De La Piedra et al., 2012) 
 
Table 5.3 Altera field-programmable gate arrays (FPGAs) (De La Piedra et al., 2012) 
 
Table 5.4 Actel field-programmable gate arrays (FPGAs) (De La Piedra et al., 2012) 
Only Actel focuses on low-power FPGAs with the class IGLOO. In particular, the device family of 
the IGLOO NANO achieves the lowest static-power consumption and size. 
A real FFT with 1024 samples requires storage of 1024 twiddle factors (512 for the real part and 
512 for the imaginary part) with 16-bit representation. Therefore, a total non-volatile memory space 
of 16,384 bits would be needed. An alternative, a CORDIC unit can be used to generate the twiddle 
factors (Francois Philipp & Manfred Glesner, 2013). In this work, the authors benchmarked the 
dynamic power consumption for a feature extraction process based on 512 samples (16-bit fixed 
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point) complex FFT implemented on the IGLOO FPGA (AGL1005), on a Xilinx Spartan6 
(XC6SLX9, with and without using DSP resources) and a TI MSP430F1611 MCU. Based on a duty 
cycle and static power (standby mode current at 3 V for the MCU), the average power consumption 
is on the order of 𝑚𝑊 for the Spartan 6 (with and without DSP) and for the MCU, and of 𝜇𝑊 for 
the IGLOO (Francois Philipp & Manfred Glesner, 2013). They showed that the dynamic power 
consumption is similar if using the two FPGA types, lower if DSP blocks were used and higher if 
CPU. The advantage of the IGLOO FPGA over the Spartan 6 is the low static power (see Table 5.2 
and Table 5.4 for the comparison). Thanks to this feature, the IGLOO FPGA is suitable for long-
term applications that require performing the FFT with a certain duty cycle, and the platform can 
stay in sleep mode most of the time.  
Francois Philipp and Manfred Glesner (2013) used an IGLOO FPGA having a static power of about 
50 𝜇𝑊, other FPGAs of the same family have lower static power, but also fewer resources (gate 
and logic cells), and the authors declared that 75% of the total number of logic cells were used for 
three parallel multiply and accumulate (MAC) units.  
An ASIC realization of a low-power FFT hardware accelerator was presented by Kwong and 
Chandrakasan (2011), consuming 616 𝑛𝐽 for a 512 point FFT, compared to the FPGA (2514 𝑛𝐽) 
(Francois Philipp & Manfred Glesner, 2013), the energy was reduced by a factor of 4.  
Excluding the ASIC results, the energy consumption of 2514 𝑛𝐽 for FFT computation and average 
power consumption of 50 𝜇𝑊 (best case) were considered as benchmark values for MCU 
comparison. In Section 5.2.3.3, we provide a theoretical calculation of the two values (in terms of 
task-related energy and average power consumption), with a 512-sample FFT (16-bit fixed-point 
FFT) is performed each second on the MCU TI MSP430FR994.  
5.2.3.3 Microcontroller units’ performances 
As abovementioned, the MSP430FR994 MCU includes a low-energy accelerator (LEA) for signal 
processing. This peripheral shared with the CPU 8 Kbytes of RAM memory to load the data vector 
and could be called by the CPU. In addition to conventional RAM space, this class of MCU also 
has non-volatile ferroelectric random access memory (FRAM) which can be written with a lower 
current than typical flash memory. More importantly, the MSP430FR994 has several low-power 
operating modes, distinguished for the clock resources and peripherals available. As rule of thumb, 
the lower the clock rate, the lower the power consumption.   
The clock sources for the system are five in total (see Fig. 5.4): 
- two external:  
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o  low-frequency oscillator (32 KHz) (LFXTCLK) 
o  high-frequency oscillator (4–24 MHz) (HFXTCLK) 
- three internal: 
o  very low power-low frequency (10 KHz) (VLOCLK) 
o  digitally controlled (1–16 MHz) (DCOCLK) 
o  low-power oscillator (5MHz) (MDOCLK) 
  
 
Figure 5.4 b 
 
As well as for the FPGA application, the mechanism to reduce the power consumption consists in 
keeping the MCU in the low-power mode (LPM) and the wake up the CPU and enter the active 
mode (AM) only when needed.  
Here, the calculation of the average power was computed using the following approach. 
A minimum requirement was to have at least a timer to wake up the MCU every second by means 
of an interrupt routine. The timer needs to have a clock source. The LPM with the minimum power 
consumption having at least one clock source active was selected. Under this condition, the MCU 
was supposed to consume 1.2 µA at 3 V and 25 C° when sourced by the external low-frequency 
oscillator.  
The CPU clock was set at 8 MHz, so in AM the MCU consumed 1280 µA at 3 V. To calculate the 
average power consumption was therefore necessary to understand the number of cycles needed to 
complete a 512-point complex FFT. This calculation required a step from the instruction number to 
the cycle number through an understanding of the hardware architecture, which computed the 
calculations. In general, in the DSP processors the number of cycles per instruction are specified; in 
this case, a DSP library, which includes a list of processing functions (i.e. FFT) included also two 
functions to calculate the number of cycles occurred during the execution of a selected part of the 
code. The data sheet illustrating the DSP library also provided the numerical equations to obtain the 
cycles number of the main functions. 
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Based on these equations, a 512-point complex FFT was supposed to be performed in 11,136 cycles 
and, as consequence, for 8 MHz it should take about 1.4 ms. Then, the average current consumption 
was computed as follows: 
𝐼𝐴𝑣𝑒𝑟𝑎𝑔𝑒 =  𝐼𝐴𝑀 ∗ 𝑇𝐴𝑀 + 𝐼𝐿𝑃𝑀 ∗ 𝑇𝐿𝑃𝑀 + 𝐼𝑃𝐸𝑅 ∗ 𝑇𝑃𝐸𝑅 + 𝐼𝐷 ∗ 𝑇𝐷 
where 
 𝐼𝐴𝑀 is the current consumption in AM, 
𝑇𝐴𝑀 is the time the AM is on in one second, 
𝐼𝐿𝑃𝑀 is the current consumption in LPM, 
𝑇𝐿𝑃𝑀 is the time the LMP is on in one second, 
𝐼𝑃𝐸𝑅 is the current consumption related to a particular peripheral, 
𝑇𝑃𝐸𝑅 is the time the peripheral is on in one second, 
𝐼𝐷 is the current consumption for data writing and reading, and 
𝑇𝐷 is the time for data writing and reading operation in one second. 
From the datasheet the MCU, in AM consumes 1280 µA running at 8 MHz, in LPM3 1.2 µA when 
sourced from the external low-frequency crystal. Assuming 𝑇𝐴𝑀 equal to 1.4 ms (time to complete 
the FFT), then the contribution of the two terms (AM and LPM) was 3 µA (𝐼𝐴𝑀_𝑎𝑣𝑒𝑟𝑎𝑔𝑒 = 1.8 µA, 
𝐼𝐿𝑃𝑀_𝑎𝑣𝑒𝑟𝑎𝑔𝑒 =  1.2 µA). 
The timer used to trigger the AM to perform the FFT every second consume 5 µA running at 1 
MHz, but in this case, it is sourced at 32,765 KHz. Thus its consumption can be assumed to be 
around 0.1 µA. The operation of data writing is limited to the shared RAM between the LEA and 
the CPU, which is for 1024 bytes negligible. Assuming a voltage supply of 3 V, the energy required 
to compute the FFT was about 5 µJ, which doubles the FPGA performance, but the average power 
consumption is decreased by a factor of 5 (9.3 𝜇𝑊 vs. 50 𝜇𝑊).  
5.2.3.4 5.2.3.4 Firmware development and current measurement 
To validate the theoretical calculation reported in the previous paragraph, we implemented a 
firmware and tested the current consumption with a tool provided by Texas Instruments, named 
EnergyTrace Technology, with an ammeter directly on the board. To separate the power required 
for the FFT, two firmware versions were developed. The first one simply runs the MCU in LPM. 
The second uses a timer to wake up the MCU every second and perform a real FFT on 1024 
samples with a 16b-it fixed point representation. The FFT has been implemented by means of the 
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function provided by the DSP library for the MSP430FR5994. Both the software calculation and the 
ammeter measurement confirmed the theoretically predicted current and power consumption. 
5.3 Application-specific algorithm design: Real-time local field 
potentials spectral analysis 
5.3.1 Real-time frequency analysis 
As presented in Chapter 2, the control variable used by the control policy rule is the beta power 
extracted by means of Fourier analysis. The signal was acquired in buffers of a one-second length 
and smoothed with an exponential moving average without overlapping. This method allows the 
device to track beta power changes over time (see Chapter 1), but because of the low signal-to-noise 
ratio and the non-stationary nature of local field potentials (LFPs), the variance of the power 
estimation negatively impacts the stimulation voltage control. Increasing the size of the moving 
average can reduce the variance, but it also introduces additional delays and diminishes the signal-
to-noise ratio because of numerical approximations. Implementing long averages in real time 
implies two drawbacks: the first is the memorization of long buffers, which is inconvenient in terms 
of memory space and data management; the second is the use of iterative means, which may require 
unavailable decimal precision.  
The multitaper method is a non-parametrical processing method that allows the reducing of the 
variance working on a single data buffer without averaging or overlapping. The superiority of 
multitaper spectral analysis compared to a common spectrogram, in reducing the variance in power 
estimation, is widely documented (Thomson et al., 1982; Babadi et al., 2014); however, the 
computational cost is higher than that of FFT. This method is based on the multiplication of the data 
segment for a certain number of orthogonal tapers. Each tapered data set is then transformed into 
the frequency domain, and the results are averaged. The higher the number of tapers, the lower the 
variance of the estimation for effect of the average. The number of papers is, however, constrained 
by the window length and the frequency resolution.  
𝑁𝑡 ≪ 2𝑇𝑊 − 1 
Where 𝑁𝑡 is the number of tapers, 𝑇 the length of the window and 𝑊 the half-band width.  
5.3.2 Technical constraints and complexity reduction 
Because in our studies we always observed the beta power in the 5 Hz band (peak frequency +/− 2 
Hz), to be conservative, the half-band width product has to be lower than 1.5 Hz.  
 
 
 
59 
 
Technically, the maximum window size is 4 s (2048 samples at 512 Hz), because in our external 
device the harmonics of the artifact at 130 Hz were completely suppressed, we were able to reduce 
the sampling frequency to 256 Hz. If, for reasons of space and power consumption (as in 
implantable devices), it is not possible to implement an analogue low-pass filter with a sufficient 
number of poles (Stanslaski et al., 2012), then the residual harmonics equal or greater than 130 Hz 
would appear in the spectrum for sampling frequency lower than 260 Hz. For this reason, we here 
assumed as a requirement a sampling frequency of 512 Hz, the lower power of two greater than 
260 Hz.   
As stated in Francois Philipp and Manfred Glesner (2013) a 512-sample FFT with a 16-bit fixed 
points data type employs the 75% of architectural resources of modern ultra-low power FPGAs, and 
the MSP430FR5994 is optimized for an FFT size of up to 2048 samples. Using a 4 s time window 
and 1.5 half-band width allow to use up to 12 tapers, however, it results in processing each data 
window with a fixed delay of 4 s, using 4 Kbytes of non-volatile memory for each taper and 
increasing the time the MCU is in AM. We, therefore, fixed the window length at 2 s and used three 
tapers.  
The spectral analysis was tested on a data sample recorded from a PD patient who underwent one 
levodopa medication cycle. The data sample was recorded with an instrumental amplifier 
(x200,000, bandpass 1–100, notch ON), and the differential gain was set to the maximum to 
maximize the signal-to-noise ratio in order to separate the effect of the electric noise and the 
processing technique on the power estimation. In Fig. 5.5 and Fig. 5.6, we reported that the time-
frequency plot obtained with a spectrogram with rectangular windows of 2 s overlapped 50% of the 
time, and the time-frequency plot obtained with the multitaper method with 2 s time windows 
overlapped by 50% and with three tapers; we smoothed both the data with a forgetting factor equal 
to 0.98. The time axes start from 100 s to exclude from the plot the transitory time caused by the 
forgetting factor processing.  
To test how the multitaper methods improved the analysis over the simple spectrogram, we 
extracted values of the beta power in the band +/−2 Hz around the beta peak for all the time course, 
we then isolated a 100 s segment in the OFF Med condition and a 100 s in the ON Med condition. 
For both the segments, the variance and the coefficient of variation were lower. The OFF Med and 
the ON Med segment were compared in both methods (Student t-test). The processing methods 
differed between the two segments, but with the multitaper method, the level of significance was 
higher (𝑝𝑠𝑝𝑒𝑐𝑡𝑟𝑜𝑔𝑟𝑎𝑚 > 𝑝𝑚𝑢𝑙𝑡𝑖𝑡𝑎𝑝𝑒𝑟). 
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Figure 5.5 Spectrogram (periodogram) 
 
Figure 5.6 Spectrogram (multitaper method) 
5.3.3 Algorithm implementation and power consumption 
Compared to the spectrogram, the multitaper method requires additional processing: data tapering, a 
number of FFT equal to the number of tapers and averaging FFT modules.  
As mentioned above, the average current consumption for a real FFT of 1024 samples performed 
every second is 3.1 µ𝐴. To compare the spectrogram to the multitaper current requirement, we here 
focused on the FFT operation and considered the module calculation on a second analysis. For the 
above-selected parameters (T = 2 s, W = 1.5 Hz, tapers = 3), the multi-tapers analysis requires 3*N 
multiplication and three real FFTs of 1024 samples. Because 3N multiplications of 16-bit fixed-
point datatypes take 0.58 𝑚𝑠, the total time the MCU stays in AM is 4.8 𝑚𝑠, resulting in an average 
current consumption of 7.3 µ𝐴. The module of the three FFT realizations needs to be calculated and 
averaged. 
The computation of the FFT module implies square roots, multiplications, and sums; however, it 
can be simplified by calculating it for only the frequencies of interest. Following the 
abovementioned approach, we calculated the number of cycles for the calculation of the module for 
a 5 Hz band with a 0.5 Hz frequency resolution for both spectrogram and multitaper method (1.6 µ𝐴 
vs 2.5 µ𝐴). The total current consumption for the multitaper method is therefore about 9.8 µ𝐴.    
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An alternative solution to the MSP430FR5994 is the latest generation of MCUs, such as the Cortex 
M4 CPU. The Cortex M4 microprocessor differently from the previous versions have DSP 
instructions and a floating point unit (FPU). These additional features allow one to perform 
processing operations faster and with greater precision. To theoretically calculate the current 
consumption, we applied the same method used for the MSP430FR4994 to the STM32L4KC, 
which is an MCU of the family of STM32L4 (ST Microelectronics, Geneva, Swiss) with a Cortex 
M4 CPU. Despite the average current of this MCU, for the same multitaper algorithm, it resulted in 
about double the MSP430; it is still suitable for implantable devices sourced by secondary batteries, 
and because it can process 32-bit and floating point data types, it is suitable for neural signals 
having a low signal-to-noise ratio.     
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6  Discussion 
6.1 Technological considerations and further steps 
We developed an external portable LFP-based aDBS prototype intended for use in PD patients with 
externalized DBS leads. The system portability allowed us to test aDBS in ecologic conditions (i.e. 
during daily activity in perioperative experimental sessions). Before, starting the experimental 
protocols, we validated the device in vitro and in vivo.  
The main objectives of the validation procedures were to test the sensing and the processing 
functionalities. During in vitro tests, we proved that the device, despite the concurrent presence of 
stimulation artifact, estimated the power change of a sinusoidal signal, which varied in the 
amplitude of 1 µVrms. We also proved its functioning in tracking LFP spectral power changes 
during stimulation in a PD patient. The aDBS prototype extracted the beta band power in real time 
with the firmware and the expected tracking lag. The internal parameters were personalized 
according to the specific LFP spectral features of the patient with 1 Hz resolution (peak and 
frequency band). To verify that the beta power time course was associated with the patient’s clinical 
conditions and not with random changes, we applied the change point analysis, and controlled that 
the change points detected were relative to levodopa or DBS. The outputs of the change point 
analysis confirmed the relationship between the beta power modulations and the different clinical 
states.  
One drawback of the external aDBS device is that it is a single-channel device, for both recording 
and stimulating. This feature requires the use of two devices if a bilateral setting is needed. 
Moreover, the pass band of the analog front end cuts the LFPs between 2 and 40 Hz, and although 
beta band activity represents the primary choice for the control variable, it can prevent the 
possibility of recording higher frequencies such as gamma oscillations. The coupling between beta 
oscillations phase and gamma oscillations amplitude (i.e. the PAC) has been recently reported as 
possible pathophysiological mechanism of the parkinsonian state, thus being a potential candidate 
as a control variable (de Hemptinne et al., 2015; Connolly et al., 2015). Moreover, in this project, 
we focused on spectral power estimation, but higher-order analysis may prove to extract most 
robust control variables, thus requiring more processing resources.  
Other groups have investigated aDBS or new stimulation protocols with fixed platforms, ensuring 
greater processing possibilities (Rosin et al., 2011; Hauptmann et al., 2009; Little et al., 2013), but 
limiting the testing to patients unable to move. In fact, the power consumption and the space 
constraints have a negative impact on the processing possibilities, especially for implantable 
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devices that which require and hardware and firmware co-design (Rouse et al., 2012). The main 
drawback of implementing feature extraction processing in hardware is the lack of flexibility, even 
though they may be required to reduce power consumption. The implantable device presented by 
Rouse et al (2012) presents analog filters to isolate oscillations with a frequency resolution of 5 Hz 
and with a tunable band. This solution allows real-time measurement of the rectified voltage of the 
interested frequency band. Moreover, systems on chip (SoC) with digital filter banks for power 
extraction have been proposed for seizure detection devices (Verma et al., 2010). In the case of PD, 
the open questions about physiological and DBS mechanisms lead to the choice of designing 
implantable devices with explorative purposes having processing flexibility as one of the main 
requirements. Although, it was focused on FFT computation, in Chapter 5 we showed that modern 
microcontrollers can be preferred to FPGA implementations, and the ASIC solution should be 
adopted only if the entity of the calculations surpasses the MCU possibilities. It is, therefore, 
desirable that future implantable devices for neurological disorders should not be limited to 
hardware processing but include flexible reprogrammable platforms.  
The development of an external portable device provides a trade-off solution that can preserve the 
flexibility and power computation while allowing the neurologist to design experimental protocols 
where the patient can perform motor tasks relevant for the clinical evaluations (i.e. walking).  
This approach, despite being limited to perioperative experimental sessions, can therefore promote 
the understanding of PD pathophysiological mechanisms and can be extended to other neurological 
disorders (e.g. Gilles de la Tourette syndrome [Priori et al., 2013]) treated with DBS.  
6.2 Experimental and clinical considerations  
The results of our proof of concept study comparing aDBS and cDBS showed that in the presence 
of levodopa stimulation, aDBS induces similar global motor improvement with less dyskinesias 
than cDBS. Additionally, aDBS was safely delivered and consumed less power than cDBS.  
In our single case study (Rosa et al., 2015), we tested the portable prototype used in this study and 
reported that aDBS was safe and well tolerated and that it induced better control of dyskinesias than 
cDBS.  
For all our parkinsonian patients, the aDBS algorithm was able to “follow” the patient’s beta 
modulations, which we assume were related to clinical motor fluctuations. The beta reduction 
induced by levodopa decreased the stimulation voltage, resulting in aDBS amplitude lower than 
during cDBS. Our findings demonstrated several advantages in reducing stimulation through an 
aDBS approach. First, we obtained a 73.6% decrease of the energy delivered to the patient. Second, 
aDBS was more effective in reducing dyskinesias than cDBS. Our results support the idea that 
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aDBS could help clinicians limit the severity of side effects induced by the transient sum of DBS 
stimulation and pharmacological therapy. Moreover, although a reduction of the levodopa dose is 
observed for up to 10 years after DBS, antiparkinsonian treatment generally increases over time in 
patients who receive DBS (Rodriguez Oroz et al., 2012). Consequently, DBS-induced control of 
motor fluctuations tends to worsen after a number of years of DBS (Shupback et al., 2005; Zibetti et 
al., 2011). However, considering that in our experimental setup levodopa-induced dyskinesias were 
elicited by a supraliminal dose, it is difficult to draw a definite conclusion to direct improvement of 
dyskinesias.  
The improvements in the UPDRS III score elicited by aDBS were similar to those seen with cDBS, 
both when DBS was delivered alone and when concurrent levodopa treatment was administered. 
The aDBS and cDBS-induced improvements in UPDRS III scores were lower than those reported 
by other researchers in follow-up DBS studies (Deushl et al., 2006). As we choose a low maximum 
stimulation value (20% over the threshold for eliciting the 60% improvement in rigidity), this 
discrepancy can be partially explained. Aside from clinical aspects, altered by a “stunning” effect 
associated with the surgery, which can elicit a pseudo-subthalamotomic effect (Mann et al., 2009) 
that improves the motor symptoms, the aDBS proved to work properly across patients. The beta 
band power and then the stimulation voltage decreased significantly under the effect of 
dopaminergic medication, which acted as a driver of clinical and neurophysiological change. Based 
on a linear association of stimulation parameters to an observed range of variation of beta power 
values, we avoided a concurrent electrical and pharmacological treatment. 
Because the adaptive rule that we used drew on the hypothesis that beta-clinical state correlation 
across patients is also valid intra-patient, we extended the period of observation to about eight 
hours. In this prolonged study, a direct comparison with cDBS was not possible because of the 
scheduling of the surgeries did not allow us to have three entire days for testing. Each experimental 
day took about 10 hours from initial settings to final clinical evaluation. We therefore focused on 
confirming the correlation of beta oscillations, stimulation amplitude, and clinical state. We found 
that the statistical correlation was preserved, and, in OFF state, the patients experienced a 
significant improvement of the clinical state compare to the baseline condition, while the ON state 
was free of side effects such as dyskinesias.         
The parametrization methods proposed in Chapter 3 may lead, however, to overstimulation or 
understimulation when not correctly matching the (linear) correlation between the power of beta 
and the clinical state. Future research will need to overcome this issue and optimize the adaptive 
rule by means of long-term monitoring sessions.  
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The availability of concurrent physiological (beta power) and clinical (UPDRS III) data over a long 
period (one week) is feasible only in chronic conditions with implantable devices with sensing 
possibilities. A wearable device such as bracelet with accelerometer and gyroscope (Malcom et al., 
2015) proved to be able to infer the UPDRS III scores without the need of neurophysiologist. If the 
correlation between beta power and clinical state is confirmed also intra-patient, the validity of beta 
oscillations can definitely be considered a valuable biomarker of the parkinsonian state, although its 
causal role remains unproven.    
6.3 The role of beta oscillations and deep brain stimulation 
mechanisms 
How deep brain stimulation (DBS) acts on the neurophysiological mechanisms of PD is still under 
investigation and widely debated. Here, we focused on physiological mechanisms, even if 
neurochemical effects are thought to play an important role in exacerbating DBS therapeutic effects 
(McIntyre et al., 2015). 
Recording and stimulating different points of the cortico-basal ganglia network has unveiled new 
evidence about the role of beta oscillations and the DBS interaction with neural rhythms.  
Beta oscillations are recurrent over the motor networks, and in PD patient was found in the STN 
(Brown et al., 2001; Kuhn et al., 2004; Priori et al., 2002; 2004 William et al., 2002), in the GPi 
(Brown et al., 2001; Priori et al., 2002; Cassidy et al., 2002) and in the cortex (Whitmer et al., 2012; 
de Hemptinne et al., 2013). Because it was consistently reported that beta oscillations can be 
modulated by levodopa medication (Brown et al., 2001; Cassidy et al., 2002; Priori et al., 2004; Kühn 
et al., 2006, 2009; Weinberger et al., 2006; Hammond et al., 2007; Ray et al., 2008; Alonso-French 
et al., 2006), and by voluntary and involuntary movements (Cassidy et al., 2002; Priori et al., 2002; 
Kühn et al., 2004; Doyle et al., 2005; Joundi et al., 2012; Oswal et al., 2013; Foffani et al., 2005; 
Silberstein et al., 2005; Bronte-Stewart et al., 2009) it is considered a fingerprint of PD, directly 
involved in the physiological mechanisms of motor impairments. Different hypotheses have been 
formulated to interpret the role of beta oscillations in the cortico-basal ganglia network. The leading 
hypothesis is that neurons in the STN are excessively synchronized on the beta rhythm, thus 
preventing a physiological processing of the information (Brown & Williams, 2005). 
As abovementioned, it is a common knowledge that beta oscillations are present in the cortex and 
deep regions. However, the heterogeneity of the analysis methods to detect beta oscillations creates 
difficulty in comparing results between different groups. The problem is here faced by means of 
processing techniques, working on the statistical and temporal structure of the data. The question is 
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reduced to the problem of separating the peak oscillation from the background neural noise. The 
methods proposed until now are two: fitting the background noise with an opportune noise model 
(pink or red noise) or considering the oscillations overcoming a certain threshold (Rosa et al., 2011, 
and the one we used for the first study). The first case is limited by the a priori choice of the exponent 
of the power law (−1 for the pink noise, and −2 for the red noise); the background noise may follow 
a different profile, thus biasing the results. Even if the exponent is calculated by regression methods, 
the presence of very low-frequency oscillations, different from the background neural noise, 
introduce some errors in the results. The second method, calculating the mean and the SD of the 
power in a predefined band (12–35 Hz, in our study) and fixing a threshold at the mean + 1.97SD. 
This method is, however, biased by the beta oscillation itself, which contributes to the value of the 
threshold. To overcome these limitations, we used a coarse-grained analysis method to separate the 
oscillatory component of the signal from the “scale-free background noise activity.” Compared with 
He et al. (2010), we analyzed data for a shorter duration and acquired it with a narrower analog pass-
band. In the future, more structural analysis on longer recordings may help in providing a standardized 
method for LFP analysis and for clarifying the role of different frequencies. For instance, we found 
that in a single patient having two peaks in the alpha/beta band, only the lower peak at the lower 
frequency was recognized as an oscillatory activity, and it was modulated by levodopa medication. 
Findings like this may definitely shift the frequencies of interest from the beta band as 12–35 Hz to 
the alpha/low beta band, at 8–20 Hz. A recent study, for instance, reported that across patients, the 
band most strongly correlated with motor improvement is between 10–14 Hz (Neumann et al., 2016).            
Recent evidence highlights the idea that beta oscillations may not be causally linked to cortico-basal 
ganglia network abnormalities, but rather that these are epiphenomena. Local field potential recording 
in the STNs of epileptic patients (Vyes et al., 2015) and dystonic patients (Wang et al., 2016) showed 
statistically similar spectral profiles, with no difference in beta amplitude, and even in STN PAC 
movement mechanisms (Wang et al., 2016). Moreover, similar to previous work on tremor 
oscillations (4–8 Hz) that confirmed a bidirectional relationship between peripheral (sEMG) and local 
(STN) oscillations (Tass et al., 2012), a recent study proposed cortico-muscular coherence (CMC) as 
a biomarker of PD.. The exact role of beta oscillations remains an open question, as well as that of 
DBS mechanisms.     
Several studies, albeit controversial, shown that high-frequency STN-DBS can suppress beta 
oscillation in the target area (Wingeiger et al., 2006; Eusebio et al., 2011; Giannicola et al., 2011; 
Whitmer et al., 2012). Wingeiger and et al. (2006) observed a decrease in the beta power after 
stimulation with a more evident desynchronization in the signals recorded in the dorsal area of STN. 
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Conversely, Whitmer et al. (2012) showed that the central part of the STN was more sensitive to a 
gradient of stimulation than the dorsal. In other studies, however, it was not possible to observe DBS-
induced modulations in all patients (Giannicola et al., 2011) or even none (Rossi et al., 2008). 
Recent evidence has shown that stimulation at 60 Hz instead of conventional 130 Hz contributes to 
the improvement of bradykinesias while promoting low-frequency activity (Blumenfeld et al., 2015). 
These results imply that a frequency other than the amplitude has a role in the network modulation 
(Fasano & Lozano, 2014).  
Recent evidence has also shown that DBS can reduce the PAC between the phase of beta oscillations 
and amplitude of broadband gamma oscillations (50–200 Hz) recorded from the primary motor cortex 
(M1) of PD patients (de Hemptinee et al., 2015), with concurrent improvement of the clinical state. 
This study also suggests that PAC suppression is independent of concurrent beta suppression at the 
cortical level. Moreover, previous studies have demonstrated that the PAC between high-frequency 
oscillations (HFO, >200 Hz) revealed in STN recordings is reduced under dopaminergic treatment 
(Azcarate et al., 2010; Ozkurt et al., 2011). It has also been hypothesized that high-frequency activity, 
involved in movements preparation and execution mechanisms (Foffani et al., 2003), is unable to 
undergo to physiological amplitude modulations if excessively coupled with beta oscillations.    
The relevance of the electrode position, the stimulation frequency, and the involvement of gamma 
and HFOs suggests that desynchronization of beta activity may not completely explain DBS 
mechanisms, and, ultimately, demands deeper understanding of PD pathophysiology.   
Aside from advancements in basic research, empirical approaches may promote the acceleration of 
aDBS clinical research, following different pathways (see Fig. 6.2).  
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Figure 6.1 Pathways for local field potentials (LFPs)-based adaptive deep brain stimulation 
(aDBS) clinical translation 
Rosin et al. (2011) (Pathway 4, Fig. 6.2) provided the first proof of functioning of aDBS. They used 
as a control variable the spikes recorded from M1 motor cortex area in an MPTP animal model 
(macaque) and stimulated with short pulse trains (seven pulses at 130 Hz) the GPi at 80 ms after the 
occurrence of an action potential. They obtained a reduction of akinesia and concurrent suppression 
pallidal discharge rate. Such paradigms based on the cortico-basal ganglia network functional 
anatomy are, nowadays, feasible only on animal models but play a fundamental role in unveiling 
the pathophysiological mechanisms of PD and, potentially, of other neurological disorders. 
A more empirical proof of functioning has been provided by Little et al. (2013). The adaptive 
paradigm applied in this study is grounded on the “informational lesion” hypothesis, mediated by 
DBS-induced beta-oscillation desynchronization. In other words, the hyper-synchronization of 
neural oscillations in the beta frequencies is thought of as the cause of a processing impairment at 
the level of the STN; and DBS, by disrupting the abnormal activity, restores or improves the 
physiological role of the STN. To test this hypothesis, Little et al. (2013) applied a threshold at the 
mean value of the beta power (obtained from a previous recording of the patient in the same 
condition); when the system detected a beta power greater than the threshold the DBS was turned 
ON and conversely was turned OFF if it was lower. With this methodology, they obtained an 
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improvement of the patient motor state greater than cDBS in a stimulation session of a few minutes. 
This result needs, therefore, to be confirmed in a longer study with a more detailed analysis of the 
physiological significance of the choice of the threshold and the technical feasibility (Pathway 4, 
Fig. 6.2).  
To help physicians in demystifying the role of beta oscillations, different computational models 
have been proposed to explain pathophysiological and DBS mechanisms (Holt et al., 2017). These 
models can suggest closed-loop paradigms and provide a workbench for back-testing. Tass et al. 
(2003), by modeling a neural population as a network of phase oscillators, theoretical supposed that 
a coordinated-reset DBS should have a weakening effect on local synaptic strength, thus promoting 
a structural reorganization of the neural ensemble and, ultimately, a desynchronization effect on 
abnormal oscillations. Intriguingly a recent application of such paradigm to PD patients seems to 
confirm their assumptions (Adamchic et al., 2014).   
Despite, the early focus on beta oscillations amplitude, modeling (Park et al. 2012) and empirical 
studies (Moll et al., 2017) point toward the relevance of the phase. The computational model of 
Park et al. (2012), moving from the assumption of an exaggerated coupling between GPe and STN 
as cause of beta oscillations abnormalities, shown that the GPe output is sensitive to the STN input 
phase and that dopaminergic medication exacerbates its effect by changing STN the firing pattern of 
the STN. This result in part support the observations of Rosin et al. (2011), who shown that firing 
pattern more than firing rate have a key role in PD pathophysiology. If the amplitude of beta 
oscillations provides an information about the level of synchrony and thus the intensity required for 
stimulation, the phase may provide the information about the timing. Beside the empirical 
approaches, the computational modeling will promote the development of new paradigms with the 
final goal of mimicking the network mechanisms and having a closed-loop system which, rather 
than answers to the network, dynamically interacts with it.     
In this project we assumed the worst case scenario, in which it represents only an epiphenomenon of 
the parkinsonian state (Pathway 1, Fig. 6.2). Under this hypothesis, we therefore focused on 
investigating the validity of beta power as a valuable biomarker of the patients’ clinical state. In fact, 
the absence of convincing evidence about the causal link between beta oscillations and motor 
symptoms does not imply that beta power cannot be used as a control variable, as long as its 
correlation is confirmed between subjects. 
By means of an external portable aDBS device we opened the possibility to study aDBS strategies 
during perioperative sessions in freely moving PD patients. In particular, following this framework 
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we suggested that the aDBS methodology may help clinicians in the management of motor 
fluctuations while avoiding side effects such as dyskinesias.  
The same approach can be extended to more sophisticated algorithms and all patients who undergoes 
to DBS electrode implant, thus providing a unique framework, which ultimately prompts the research 
in this sector. Moreover, our technical, neurophysiological and clinical results encourage the pursuit 
of the research in chronic conditions, which would definitely allow for long-term neurophysiological 
and clinical monitoring and a better investigation of DBS mechanisms.  
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